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ABSTRACT
MATHEMATICAL MODELING AND DYNAMICAL ANALYSIS OF THE OPERATION OF
THE HYPOTHALAMUS – PITUITARY – THYROID (HPT) AXIS IN AUTOIMMUNE
(HASHIMOTO’S) THYROIDITIS

Balamurugan Pandiyan, B.S., M.S.
Marquette University, 2011

This thesis is a mathematical modeling study of the operation of the negative feedback
control through the hypothalamus-pituitary- thyroid (HPT) axis in autoimmune (Hashimoto’s)
thyroiditis. Negative feedback control through the HPT axis is a mechanism in which the high
levels of thyroid hormone; free thyroxine (FT4) in the blood inhibits the secretion of the pituitary
hormone, thyroid stimulating hormone (TSH) into the blood. Similarly, the low levels of free
thyroxine (FT4) sensed by the pituitary gland and then it secretes thyroid stimulating hormone
(TSH) into the blood. Autoimmune (Hashimoto’s) thyroiditis is a disease in which the immune
system turns against the thyroid follicle cells and destroys them slowly for a long period of time.
This in turn interrupts the operation of the negative feedback control, in fact, the HPT axis. The
half-life of thyroid stimulating hormone (TSH) and free thyroxine (FT4) is one hour and seven
days respectively in the blood. This implies that thyroid stimulating hormone (TSH) changes in a
faster time scale than free thyroxine (FT4) both in the healthy and diseased thyroid gland. Thus,
the operation of negative feedback control is at least in two different time scales. The normal
reference range for TSH and FT4 is used in this thesis are
and
respectively. In thyroid clinics, in general, physicians see three different kinds of patients
with autoimmune (Hashimoto’s) thyroiditis with or without goiter (enlarged thyroid gland).
i)
Patients with euthyroidism (normal FT4 and TSH levels).
ii)
Patients with subclinical hypothyroidism (normal FT4 but TSH above normal
levels).
iii)
Patients with overt (clinical) hypothyroidism (low FT4 and TSH above normal
levels).
Usually patients with euthyroidism progress to subclinical hypothyroidism and then progress to
overt hypothyroidism. This is a sequential event, but in some patients’ cases, it is not true.
To describe the operation of the feedback control in autoimmune (Hashimoto’s)
thyroiditis, we developed a mathematical model in this thesis involving four clinical (state)
variables, thyroid stimulating hormone (TSH), free thyroxine (FT4), anti-thyroid antibodies
(TPOAb and TGAb), and the functional size of the thyroid gland (T). The first three variables are
regularly measured in thyroid clinics to determine the function of negative feedback control and
the status of the thyroid gland in autoimmune thyroiditis. The last variable is determined through
relationships between the other three variables and is required for this work to accurately track
the output of the gland. The problem of two different time scales is addressed using singularly
perturbation theory. Also, the analysis of the mathematical model establishes stability and
conditions under which the diseased state can be maintained the slow movement of the
functioning of the negative feedback control toward the diseased state equilibrium.
In this thesis, the purpose of modeling the operation of negative feedback control is to
describe the natural history of autoimmune (Hashimoto’s) thyroiditis. This means to describe the
natural course of euthyroidism, subclinical hypothyroidism or overt hypothyroidism for every

patient with autoimmune thyroiditis. Although, we have used four variables in modeling the
feedback control through the HPT axis, the end product depends on the levels of thyroid
stimulating hormone (TSH) and free thyroxine (FT4). In addition, the clinical chart is developed
based on the levels of thyroid stimulating hormone (TSH) and time. To validate the model
description, patient’s dataset are employed in chapter 5. For this thesis, the dataset is obtained
from Sicilian adult population, Italy through our clinical collaborator.
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Figure 1.1: The Thyroid Gland
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thyroglobulin (TG) in the colloid.
Figure 1.3: This figure shows the HPT axis. The sign (-) indicates the existence of a negative
feedback loop. Note that free thyroid hormones (T3 and T4) are sensed by the pituitary gland and
the hypothalamus.
Figure 1.4: A chronic immune response to the thyroid gland interrupts the normal function of the
HPT axis. The dotted lines represent the dormant part of the HPT axis. The solid line from
hypothalamus to pituitary to thyroid gland is the active part of the axis.
Figure 1.5: The figures (A and B) show 45 patients with autoimmune thyroiditis from group1.
Figure A shows patient’s TSH versus free T4. Figure B shows patient’s log (TSH) (mU/L) versus
free T4(pg/mL). All patients have anti-thyroid antibodies but untreated clinically because free T4
levels are normal. 2d plots show how each patient is different in the dataset. The solid red lines
indicate the reference range of TSH. The dotted red line indicates the new upper reference limit
of TSH.
Figure 1.6: 3d plots (C and D) show that all patients from group1 have anti-thyroid peroxidase
(TPOAb) and/or anti- thyroglobulin (TGAb) in their blood serum. Group1 patients are always
untreated. Figure C shows patient’s free T4 (pg/mL), TPOAb (U/mL) and TSH (mU/L). Figure
D shows patient’s free T4 (pg/mL), TGAb(U/mL) and TSH(mU/L).
Figure 1.7: 2d plots (E and F) show treated patients from time zero from group2. Group2
contains 51 patients with autoimmune thyroiditis. Figure E shows patients TSH versus free T4.
Figure F shows patient’s log (TSH) versus free T4. Comparing Figures F and B, we see that
treated patients from time zero has perfect inverse log/linear relationship between log (TSH) and
FT4 than always untreated patients.
Figure 1.8: 3d plots (G and H) show treated patients from time zero from group2. All treated
patients live with anti-thyroid peroxidase (TPOAb) and/or anti-thyroglobulin (TGAb) in their
blood serum. Figure G shows patient’s free T4 (pg/mL), TPOAb (U/mL) and TSH(mU/L). Figure
H shows patient’s free T4(pg/mL), TGAb(U/mL) and TSH(mU/L).
Figure 1.9: 2d plots (I and J) show patients from group3. Group3 contains 22 patients with
autoimmune thyroiditis. Figure I shows how patient’s progress from euthyroidism to
hypothyroidism both in terms of TSH and free T4. Figure J shows the data of 22 patients from
group3 before treatment. All patients in Figure J progress from euthyroidism to hypothyroidism
while free T4 within laboratory reference range adopted for this project. In Figure J, the data
seems to be more scattered than Figure I.
Figure 1.10: 3d plots (K and L) show patients from group3. It appears that group3 contains more
anti-thyroid peroxidase antibodies rather than anti-thyroglobulin antibodies. Figure L shows
group3 patients with TPOAb(U/mL). Figure L shows group3 patients with TGAb(U/mL).
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Figure 1.11: 2d plots (M and N) show a patient from group1 and group3. Figure M shows
patient 103 from group1 while Figure N shows patient 114 (before treatment) from group3.
Figure 1.12: The 2d scatter plot showing a linear regression model and the statistical quantities
(R2 and ρ). It seems R2 = 0.3243, (p < 0.001) and Pearson’s correlation
negative.
This indicates that there is a linear relationship between log (TSH) (mU/L) and FT4 (pg/mL).
This relationship is due to the functioning of the HPT axis.
Figure 3.1: The figure shows that
value does not change the stability of the euthyroid (steady)
state but changes the nature of the euthyroid state. Note that the euthyroid state is independent of
.
Figure 3.2: The plot of free T4 and the thyroid functional size
as a function of time of a
simulated individual. Note the thyroid functional size
is in milliliters. We start the reduced
(2d) model at the initial state
, having free T4 and within the
reference range (normal), and using parameter values from the Table A2 in Appendix A except
for . Here
. The 2d reduced system predicts that the imaginary
individual probably develops a goiter before asymptotically approaches the euthyroid
state
in approximately 60 days.
Figure 3.3: The phase plane view of the previous time series plot. Note the thyroid functional
size
is in milliliters. Here
the monitored values. The reduced
2d system asymptotically approaches the euthyroid state
.
Figure 3.4: Note the thyroid functional size
is in milliliters. We start the reduced (2d) model
at the initial state
, having free T4 above the upper reference limit
of free T4 and T normal (hashitoxicosis), and using parameter values from the Table A2 in
Appendix A except for . Here
. The 2d reduced system predicts
that the imaginary individual asymptotically approaches the euthyroid state
in
approximately 60 days.
Figure 3.5: The phase plane view of Figure 3.4. Note the thyroid functional size
is in
milliliters and
. The reduced 2d system asymptotically approaches
the euthyroid state
from hashitoxicosis state
.
Figure 3.6: Note the thyroid functional size
is in milliliters. We start the reduced (2d) model
at the initial state
, having free T4 below lower reference limit of
free T4 and T normal (clinical hypothyroidism), and using parameter values from the Table A2 in
Appendix A except for . Here
. The 2d reduced system predicts
that the imaginary individual asymptotically approaches the euthyroid state
in
approximately 60 days.
Figure 3.7: The phase plane view of Figure 3.6. Note the thyroid functional size
is in
milliliters and
. The reduced 2d system asymptotically approaches
the euthyroid state
from clinical hypothyroidism state
.
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Figure 3.8: Note the thyroid functional size
is in milliliters. We start the original (4d) model
at the initial state
, having TSH, free T4 outside
the reference range (clinical hypothyroidism), T and Ab normal, plus using the parameter values
from Table A2 in Appendix A except for . Here
. The 4d
system predicts that the imaginary individual asymptotically approaches the euthyroid
state
in approximately 60 days. Also, observe that TSH quickly
approaches the euthyroid state suggestive of the existence of a fast-time-scale for TSH.
Figure 3.9: 3d phase space view of Figure 3.8. Note the thyroid functional size
is in
milliliters and
. The reduced 2d system asymptotically
approaches the euthyroid state
from clinical hypothyroidism
state

. Using the algebraic equation,

,

is computed for the 2d system.

The 4d system asymptotically approaches the euthyroid state
clinical hypothyroidism state
approximates the 4d system. Also,

from

. Note: the reduced 2d system
is a small fixed value.

Figure 4.1: Note the thyroid functional size ( is in milliliters. The 4d system, (2.2) – (2.17)
with the initial condition
for the parameter values from Table A2, predicts that
Ab concentration asymptotically approaches zero in approximately 350 days while other
variables remain at steady state. This means that the anti-thyroid antibodies did not affect the
function of the HPT axis.
Figure 4.2: For
and the parameter values from Table A2, the 4d system, (2.2)
– (2.17) moves from the initial state
to euthyroid steady
state
. Note the thyroid functional size ( is in milliliters.
Figure 4.3: If the initial state
is taken on the slow
manifold, not at euthyroid state, then the 4d system, (2.2) – (2.17) for the parameter values from
Table A2, predicts that the trajectory converges to euthyroid state. This suggests the euthyroid
state is asymptotically stable. Since
, the diseased steady state is not on the surface. Note
the thyroid functional size ( is in milliliters.
Figure 4.4: We started the 4d system, (2.2) – (2.17) from
=
and the numerical solutions of the system approaches euthyroid state. Since
diseased steady state is located in the negative octant, so we did not plot the green dot
(representing diseased state).

, the

Figure 4.5: For the initial state
, the 4d system (2.2) – (2.17) for the parameter
values from Table A2 predicts that Ab concentration asymptotically approaches 6800 in
approximately 2 years while other variables start at euthyroid state. Note the thyroid functional
size ( is in milliliters.
Figure 4.6: For the initial state
and
, the 4d system (2.2) –
(2.17) for the parameter values from Table A2 predicts that euthyroid state becomes unstable, and
the trajectory approaches the diseased state.

x
Figure 4.7: If the initial state
) is taken on the level
curve, not at euthyroid state, then the 4d system, (2.2) – (2.17) for the parameter values from
Table A2, predicts that the trajectories approaches the diseased state (subclinical hypothyroidism)
while euthyroid state becomes unstable and shows saddle-type behavior. Note the thyroid
functional size ( is in milliliters.
Figure 4.8: This figure shows the stability of diseased steady state, the initial state was chosen at
. The reduced system, (2.26) – (2.28) approaches the diseased state
via euthyroid state. Note the saddle-like behavior near the euthyroid state. Here,
. Note the thyroid functional size ( is in milliliters.
Figure 4.9: A bifurcation diagram shows a transcritical bifurcation for a range of values . The
local bifurcation takes place at
.
Figure 4.10: This bifurcation diagram illustrates how the anti-thyroid antibodies steady state
concentrations
changes as
varies in the model from 0 to 5. Note that the bifurcation
occurs at
.
Figure 4.11: This bifurcation diagram shows how free T4
steady state concentrations
changes as varies from 0 to 7. Observe that the bifurcation occurs at
and when
, we see a patient would have clinical hypothyroidism (see the baseline value of free T4,
shown as a solid magenta line).
Figure 4.12: This bifurcation diagram shows how
steady state concentrations changes as
varies from 0 to 7. Also, observe that the bifurcation occurs at
and when
,
resulting in clinical hypothyroidism. Thus, the model suggests that at
, TSH upper reference
limit is 2.3 mU/L (approximately). The diseased steady state is still inside the box.
Figure 4.13: This bifurcation diagram shows how the functional size of thyroid gland
changes as varies from 0 to 7. Also, observe that the bifurcation occurs at
.
Figure 5.1: This figure shows Case 1: euthyroidism euthyroidism chart. Note: The solid red
lines illustrate the normal reference range for TSH. The dotted red line chosen for this project as
an upper TSH reference limit. The green solid line indicates that the 4d system, (2.2) – (2.17)
approaches the euthyroid (steady) state for ten different
values less than . The initial state of
the 4d system is
. The parameter values are all from
Table A2 in Appendix A.
Figure 5.2: This figure shows euthyroidism subclinical hypothyroidism chart. Note that all
solutions go to subclinical diseased steady state. We simulated the 4d system, (2.2) – (2.17)
with the initial state
and the parameter values from Table A2 with six different
values between
(2.3412) and up to
.
Figure 5.3: 2d view of euthyroidism subclinical hypothyroidism chart. We simulated the 4d
system with the initial state
and the parameter values from Table A2 but
different values, between
(2.3412) and up to
. The curve in this picture is
parameterized by six different values, that is,
. For every

xi
, we have a diseased steady state (subclinical), that is shown in the picture with a green
dot. The euthyroid state is shown in the picture with a red dot.
Figure 5.4: log

mU/L versus freeT4

pg/mL view of the previous Figure 5.3.

Figure 5.5: This figure shows the euthyroidism → subclinical → clinical hypothyroidism chart.
To generate this picture, we picked eleven different
values greater than
and then
simulated the 4d system with initial condition
. The parameter values are all
from Table A2.
Figure 5.6: 2d view of euthyroidism → subclinical → clinical hypothyroidism chart. We
simulated the 4d system with the initial state
and the parameter values from
Table A2 but different
values. The curve in this picture is parameterized by eleven different
values greater than
. For every
, we have a diseased steady state (clinical
hypothyroidism), that is shown in the picture with a green dot. The euthyroid state is shown in the
picture with a red dot. Note an individual progress to clinical hypothyroidism via subclinical
hypothyroidism.
Figure 5.7: log

mU/L versus freeT4

pg/mL view of the previous Figure 5.6.

Figure 5.8: Clinical staging chart. This chart can be used to determine the natural course of
subclinical or clinical hypothyroidism or euthyroidism by moving the graph up and down
according to the patient’s set point (see Validation of Model with Data Section). Note we
simulated all these curves with different
values in the 4d system using an imaginary
individual’s table parameter values from Appendix A.
Figure 5.9: Combing Figures 5.7 and 5.4 yields the above parameterized curve. This
parameterized curve belongs to an imaginary individual that we picked for this project (see
Appendix A). Since the model (2.2) – (2.17) is patient-specific, each patient has their own curve
depending on their parameter values and the normal value of the HPT axis. The euthyroid state is
shown in the picture with a red dot and diseased steady states are shown with green dots.
Figure 5.10: This figure illustrates patient (#99) natural history of euthyroidism in euthyroidism
euthyroidism chart. It seems patient’s
value remains at the euthyroid steady state for 40
months. This patient’s euthyroid state for
value is
mU/L
Figure 5.11: This figure illustrates patient (#103) natural course of subclinical hypothyroidism in
euthyroidism subclinical hypothyroidism chart. It seems this patient’s TSH value continuously
increases as time increases. By looking at 3 data points in this chart, we could predict that TSH
cannot go beyond
mU/L at least for 40 months. Thus, this patient may have chance to become
subclinical hypothyroidism throughout his life time unless there is some triggering event that
changes the nature of the immune response and thus .
Figure 5.12: This figure shows the natural history of patient (#114). This patient reaches clinical
hypothyroidism via subclinical hypothyroidism. Note this patient’s TSH value increases
continuously but did not exceed mU/L in 40 months.
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Figure 5.13: To generate this 2d picture, log
(mU/L) versus free T4
(pg/mL). We
simulated the 4d system with patient (#103) parameter values from Table 5.1. Here
was
and the initial (euthyroid) state was
. Note:
the diseased steady state is located within the normal free T4 reference range. So, the model
predicts that the patient (#103) may remain in subclinical hypothyroidism unless the immune
response of this patient changes in the future.
Figure 5.14: To generate this 2d picture, log
(mU/L) versus free T4
)(pg/mL). We
simulated the 4d system with patient (#114) parameter values from Table 5.1. Here
was
and the initial (euthyroid) state was
. Note:
the diseased steady state is not located within the normal free T4 reference range. So, the model
predicts that the patient (#114) will definitely become clinical hypothyroidism patient in the
future.

INTRODUCTION TO A MEDICAL PROBLEM
The thyroid stimulating hormone (TSH), a key hormone, is synthesized and secreted into the
blood by the pituitary gland. In response to TSH, the thyroid gland secretes thyroxine (T4) into
the blood, in which 99% of T4 binds to proteins in blood serum such as thyroxine binding
globulin, albumin and the remaining 1% circulates as free thyroxine (FT4). This in turn inhibits
the secretion of TSH in the pituitary gland. This mechanism is called a negative feedback control
through the hypothalamus-pituitary-thyroid (HPT) axis. The existence of the negative feedback
control is to maintain the adequate levels of free thyroxine (FT4) in the blood, which, in the
clinical setting, referred to a set point of the HPT axis. The set point of the HPT axis varies
greater between individuals than in the same individual sampled repeatedly over time (Andersen
et al. 2002).
Autoimmune (Hashimoto’s) thyroiditis is a complex disorder in which the immune
system attacks the thyroid gland with both proteins and immune cells such as T cells, and
cytokines for long periods. More precisely, as one aspect of autoimmune thyroiditis, the immune
system produces proteins (thyroid peroxidase antibodies, TPOAb and thyroglobulin antibodies,
TGAb) against the thyroid follicle cell membrane proteins (thyroid peroxidase, TPO and
thyroglobulin, TG) in the blood. These proteins (TPOAb and TGAb) induce thyroid follicle cell
lysis by binding with TPO and TG respectively. Thus, autoimmune thyroiditis interrupts the
normal thyroid operation and eventually disrupts feedback control. Consequently, one develops
symptoms (like, goiter),signs (like, hyperactivity), and some clinical conditions, like,
euthyroidism (normal FT4and TSH levels in the blood), subclinical hypothyroidism (normal FT4,
but TSH above normal levels),overt (clinical) hypothyroidism (underactive thyroid gland- low
FT4 levels and TSH above normal levels) or hashitoxicosis (transient hyper to hypothyroidism).
Hashitoxicosis is a life-threatening abnormal clinical condition. It is one of the rare presentations
of autoimmune thyroiditis, approximately 5% of all autoimmune thyroiditis patients.
1
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From the clinical viewpoint, the presence of anti-thyroid antibodies in blood serum is the
hallmark of this disease and has been considered as a diagnostic tool of autoimmune thyroiditis in
healthy and asymptomatic individuals. Their presence in normal individuals is the risk factor for
overt hypothyroidism and also believed that, antibodies induce thyroid damage for long periods
until hypothyroidism is clinically become evident. As a result, the set point of the HPT axis
changes for long periods along with damaging thyroid gland. So, in this thesis, a mathematical
model will be constructed to track the changes of the set point, in other words, the development
of overt hypothyroidism. On the other hand, the absence of anti-thyroid antibodies is strong
evidence against autoimmune thyroiditis (Shoenfeld et al 2007). Therefore, individuals with antithyroid antibodies (TPOAb and TGAb) considered being autoimmune (Hashimoto’s) patients in
the clinical setting.
In clinical practice, in general, physicians see three different kinds of patients with
autoimmune (Hashimoto’s) thyroiditis with or without goiter.
a) Patients with euthyroidism (normal FT4 and TSH levels).
b) Patients with subclinical hypothyroidism (normal FT4 but TSH above normal levels).
c) Patients with overt (clinical) hypothyroidism (low FT4 and TSH above normal
levels).
Usually patients with euthyroidism progress to subclinical hypothyroidism and then progress to
overt hypothyroidism. This is a sequential event in most patients. But, euthyroidism in some
patients may persist for many years even lifelong. This means to say that overt hypothyroidism is
not an obligated evolution of the autoimmune thyroiditis. Similarly subclinical hypothyroidism
in some patients may persist for many years even lifelong. It means to say that again overt
hypothyroidism is not an obligated evolution of the autoimmune thyroiditis. Overt
hypothyroidism is the end stage of the course of autoimmune thyroiditis where patients need
thyroid hormone replacement treatment. Levothyroxine (synthetic free thyroxine) is commonly
used drug as thyroid hormone replacement. The half-life of thyroid stimulating hormone (TSH)
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and free thyroxine (FT4) is one hour and seven days respectively in the blood. This implies that
TSH changes in a faster time scale than FT4. Thus, the operation of negative feedback control is
at least in two different time scales.
To describe the operation of negative feedback control, that is, the HPT axis, in
autoimmune thyroiditis, patient-specific mathematical model is required and will be developed in
this thesis. The model is patient-specific since all autoimmune patients are different. Modeling is
done with ordinary differential (rate) equations. Moreover the problem of two different time
scales is addressed using singularly perturbation theory.

Outline of Thesis
Chapter 1 provides the background materials required for this thesis, such as, physiology of the
thyroid gland, the HPT axis, autoimmune thyroiditis, and clinical staging. In autoimmune
thyroiditis, the clinical evidence suggests that the hypothalamus-pituitary function is intact and
the thyroid-pituitary function is interrupted. That is, to say that one part of the operation of
negative feedback control is normal and the other part is abnormal (see Figure 1.3). To observe
this phenomenon in the dataset, we presented several graphs showing the abnormal behavior of
the HPT axis. As a final result of the Chapter 1, we established the patient-specific clinical
staging criterion for patients with autoimmune thyroiditis. The staging criterion has three general
cases, namely euthyroidism

euthyroidism, euthyroidism

euthyroidism

clinical hypothyroidism.

subclinical

subclinical hypothyroidism and

Chapter 2 provides a four dimensional (4d) non-linear model for patients with
autoimmune thyroiditis. To construct this model, we used four clinical variables. Out of four,
three of them are clinically measurable quantities, thyroid stimulating hormone (TSH), free
thyroxine (FT4), and anti-thyroid antibodies (TPOAb and TGAb) and the other, the functional

4
size of the thyroid gland (T) 1 can be measured through relationships with other three variables.
The model takes the form of a singularly perturbed initial value problem due to the presence of at
least two-time scales. Singular perturbation theory is the main tool for the analysis of a model,
which is elaborated in this chapter. The model has eleven parameters - some parameters are
available from the literature and most are estimated through the equilibrium arguments. But three
parameters, namely,

and

turned out to be the governing parameters of the system.

Through further investigation in Chapter 4, we noticed that

is an important parameter and with

that we could describe the dynamics of all autoimmune thyroiditis patients.
Chapter 3 provides the special case of the four dimensional (4d) non-linear model. That
is, investigate the 4d model in the aspect of absence of anti-thyroid chronic immune response.
This resulted in the three dimensional (3d) non-linear model. We found that 3d model has one
steady state (set point of the HPT axis) in the positive octant, in fact, inside the trapping
rectangular box. In Chapter 3, we referred the steady state to euthyroid state and the arguments
for constructing rectangular box have elaborated. Through linear stability analysis, we proved
that euthyroid state is always stable in the box. Using singular perturbation arguments, we
showed that all solutions are attracted to this euthyroid (steady) state.
Chapter 4 provides the analysis of the dynamics of the 4d model. We constructed a
rectangular box in 4d space such that the euthyroid (steady) state is trapped inside the box.
Furthermore, through local stability analysis, we found that
system, in fact, a bifurcation parameter. As
we obtained two critical values, one

is an important parameter in the

changes from zero to the larger range of values,

and another

. When

, the box contains only

one steady state which is the euthyroid state and the diseased steady state located in the negative
orthant. As

changes in the system, the diseased steady state moves towards the box and when

, the diseased steady state merges with the euthyroid (steady) state. When

1

The clinical variable T means the functional size of the thyroid gland as opposed to the thyroid size

, the
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diseased steady state emerges into the rectangular box and becomes stable – we showed that
through local stability analysis. But when

reaches the value of

concentrations goes below the lower reference range
hypothyroidism. Therefore, we conclude that, when

, free thyroxine (FT4)

which means clinical
is below the critical value

, patients

with autoimmune thyroiditis do not develop the consequences of autoimmune thyroiditis. When
is in between

and up to

hypothyroidism. When

, patients with autoimmune thyroiditis develop subclinical

is greater than

, then patients develop subclinical hypothyroidism

and eventually become clinical hypothyroidism.
Chapter 5 implements the results of Chapter 4 through clinical staging criterion described
in Chapter 1. This in turn results in clinical staging charts. It is the main result of this thesis.
The charts are mainly based on TSH because test results of TSH are more reliable in autoimmune
thyroiditis. We have given the discussion of how one could use the clinical chart in thyroid
clinics for all autoimmune patients to describe the natural history and to predict the eventual TSH
value of particular patient. In addition to clinical chart, we presented the dynamics in two
dimensional (TSH versus FT4) phase plane parameterized by

. Also, we validated the

mathematical model using patient’s dataset in order to verify the model’s ability to describe the
natural history of autoimmune thyroiditis.

CHAPTER 1 – BACKGROUND MATERIAL
In this chapter, we introduce the background material required for this mathematical modeling
work. The background material mainly focuses on the operation of the hypothalamus-pituitarythyroid (HPT) axis both under healthy and diseased thyroid gland. The healthy thyroid gland
preserves the normal operation of the HPT axis while the diseased thyroid gland interrupts the
normal operation of the HPT axis with the thyroid unable to produce adequate amounts of thyroid
hormones. The diseased thyroid gland in this work is the consequence of autoimmune
(Hashimoto’s) thyroiditis.

1.1

Introduction to Thyroid Physiology

General Anatomy

The thyroid is the largest endocrine gland, located in front of the neck just below the larynx or
above the collar bones (see Figure 1.1). The thyroid gland is butterfly-shaped and consists of two
wings, called lobes and attached through a middle part called the isthmus. In healthy state, the
normal adult thyroid gland weighs approximately 10 - 20 g and each lobe of thyroid measures
about 2.5 - 4 cm in length, 1.5 - 2 cm in width, and 1 - 1.5 cm in thickness, but in diseased state,
the thyroid weight and size are variable (see Greenspan and Gardner, 2001).
Function of the Thyroid Gland

Thyroid stimulating hormone (TSH) is synthesized and secreted into blood from the pituitary
gland. In response to TSH, the thyroid gland produces triiodothyronine (T3) and thyroxine (T4)
and secretes them into the blood. This is the main function of the thyroid gland. These hormones
in turn control the metabolic rate in human body. The main thyroid hormone is thyroxine (T4),
which contains four iodine molecules, whereas triiodothyronine (T3) contains three iodine
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molecules. In the healthy state, the daily thyroid gland production of T4 is about
daily production of T3 is about

. The

, of which about 20% is produced by the thyroid gland and

80% by deiodination of T4 in extra thyroidal tissues (Bunevicius et al. 1999). T4 molecules are
active longer in the blood than T3, but T3 molecules are more biologically active at the cellular
level. Further, approximately 99.98% of T4 in blood binds with plasma proteins (such as
thyroxine binding globulin (TBG) (60-75%), prealbumin/transthyretin (15-30%), and albumin
(~10%)(Werner et al. 2005; Robbins and Rall, 1960)) and circulates as bound T4 - the remaining
0.02% circulates as free (unbound) T4. Similarly, (~ 99.7%) of T3 in blood binds with plasma
proteins, specifically, TBG. In the clinical setting, free T4 and TSH are considered to be the most
reliable measure to determine the status of the thyroid gland (Surks et al. 1990). Their normal
reference ranges for adult populations for free T4 and TSH are usually between
and
4.0

(Baloch et al. 2003) respectively. Note that TSH upper reference limit is
. But TSH upper reference limit is a controversial subject, so nowadays, researchers

suggest to decrease the upper normal range of TSH to 2.5
clinical observation that patients with TSH between 2.5 to 4

(Surks et al. 2005) due to the
have increased risk of

progression to hypothyroidism (underactive thyroid gland).
Thyroid Follicles

The functional unit in the thyroid gland is the follicle. The follicle consists of thyroid follicle cells
surrounding colloid. Colloid is the central region in the follicle, and contains the raw materials for
thyroid hormone production such as thyroglobulin (TG), iodine, thyroid-peroxidase (TPO), and
other proteins. The microscopic findings indicate that the shapes and sizes of the follicles are
irregular (Greenspan and Gardner, 2001), but for modeling purposes, one typically assume
follicles are roughly spherical in shape (Degon et al. 2004) (see Figure 1.2). But, in our model,
the shape and size do not matter. Furthermore, blood vessels, lymphatics, parafollicular cells (C-
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cells) and fibrous tissues all surround the follicles and they are completely covered by a network
of capillaries.
Thyroid Follicle Cells

The follicle cells controls the secretion of thyroid hormones in blood based on the level of
stimulation from the pituitary gland by TSH. The follicle cells become columnar (i.e., elongated
and rectangular) when stimulated by TSH and are flat when resting. These follicle cells are the
victims in Hashimoto’s thyroiditis. Charles et al. (1996) noted that the size of the follicles
depends on the number of follicle cells and the amount of colloid. If the follicle cells die under
the diseased state, then it causes the size of the follicles to shrink significantly and results in
decreased thyroid hormone production from that follicle.
In the diseased state, the immune cells infiltration a region of the thyroid gland and their
destructive action makes that region non functional or not active. Thus, the affected region is
unable to respond to TSH and produce thyroid hormones. Therefore, for our work, we consider
the active part of the gland (the functional part of the thyroid gland) which is able to respond to
TSH and produce thyroid hormones. The size of this active part of the gland we call the
functional size of the thyroid gland.

1.2

The Hypothalamus - Pituitary - Thyroid (HPT) Axis

If the blood levels of free thyroid hormones (T3 and T4) become too low (below a set point), then
the hypothalamus senses the reduction of free thyroid hormones and secretes thyrotrophic
releasing hormone (TRH) which stimulates the pituitary gland to make and secrete TSH into the
blood. This in turn stimulates thyroid follicle cells to secrete thyroid hormones (T3 and T4) into
the blood. If the blood levels of free thyroid hormones become too high, and then the
hypothalamus and/or pituitary gland senses the high levels of free thyroid hormones and reduces
its secretion of TRH and TSH, which in turn slows down the production of thyroid hormones in
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thyroid follicle cells. This type of control mechanism is a negative feedback loop the control
through hypothalamus - pituitary - thyroid axis (see Figure 1.3) (Brown-Grant, 1957; Zoeller et
al. 2007).
The principal purpose of the existence of the HPT axis is to maintain the set point of
TSH, and free thyroid hormones (T3 and T4) within the normal reference range. The set point
and normal reference range changes from person to person and it depends on many factors such
as age, gender, genes, body weight and race (Panicker et al. 2008). For instance, in children, the
HPT axis undergoes progressive maturation and modulation until puberty resulting in continuous
changes in the set point and normal reference range (Nelson et al. 1993). In general, children
have higher TSH and lower thyroid hormone levels. On the other hand, higher TSH levels and
lower thyroid hormones are reported in the elderly people (Surks and Hollowell, 2007),
suggesting that elderly people have different normal set points for TSH and free thyroid
hormones (T3 andT4). In general, in healthy people, variability in TSH, and free thyroid
hormones (T3 and T4), is greater between individuals than in the same individual sampled
repeatedly over time, suggesting that different people have different set points for the function of
HPT axis (Andersen et al. 2002).

Figure 1.1: The Thyroid Gland
(see http://nursingninjas.com/nursingschoolblog/2010/05/medical-surgical-rotation/functions-ofthyroid-hormones/)
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Figure 1.2: This figure shows a typical follicle from the thyroid gland. It is roughly spherical in
shape with normal follicle cells, thyroid receptors (TSHR), thyroid peroxidase (TPO) and
thyroglobulin (TG) in the colloid.

Figure 1.3: This figure shows the HPT axis. The sign (-) indicates the existence of a negative
feedback loop. Note that free thyroid hormones (T3 and T4) are sensed by the pituitary gland and
the hypothalamus.
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1.3

Hypothyroidism and its Types

Hypothyroidism is an underactive thyroid gland, which means the thyroid gland does not produce
enough thyroid hormones to stay in the reference range (Silverman and William, 1997; Ord,
1878). The result of hypothyroidism is the slowing down many bodily functions, most
importantly, metabolism. Hypothyroidism is also known as myxoedema. For the hypothyroidism
condition, the patients are treated clinically with synthetic thyroxine pills, called Levothyroxine,
which they must take every day for their entire life (Papapetrou et al. 1972). There are three main
types of hypothyroidism, namely primary, secondary and tertiary, which result from the
dysfunction of the thyroid gland, the pituitary, and the hypothalamus respectively.
Primary Hypothyroidism

An individual is said to have primary hypothyroidism if the thyroid gland does not produce
enough of thyroid hormones, but the pituitary and hypothalamus are normal. Primary
hypothyroidism occurs mainly due to autoimmune (Hashimoto’s) thyroiditis or due to lack of
dietary iodine. We discuss primary hypothyroidism in detail in next section after the introduction
of autoimmune (Hashimoto’s) thyroiditis.
Secondary Hypothyroidism

An individual is said to have secondary hypothyroidism if the pituitary gland does not produce
enough of TSH which stimulates the thyroid gland to produce the thyroid hormones, but the
thyroid and hypothalamus are normal. Secondary hypothyroidism occurs in pituitary tumors,
radiation and after surgery.
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Tertiary Hypothyroidism

An individual is said to have tertiary hypothyroidism if the hypothalamus does not secret
thyrotropin releasing hormone (TRH) which stimulates the pituitary gland to produce TSH, but
the thyroid and pituitary are normal.
Symptoms

The general symptoms of hypothyroidism are fatigue, drowsiness, forgetfulness, difficulty with
learning, dry and itchy skin, puffy face, constipation, sore muscles, weight gain and heavy
menstrual flow. The symptoms are variable among patients; so the only way to know for sure
whether the patient has hypothyroidism is via blood tests. We will discuss the thyroid function
test below.

1.4

Autoimmune (Hashimoto’s) Thyroiditis

Hashimoto’s thyroiditis or autoimmune thyroiditis, also called chronic lymphocytic thyroiditis, is
caused by the abnormal immune response to components of the thyroid gland by means of both
the cellular and humoral response (Chistiakov, 2005). This cellular and humoral immune
response results in production of T-cells, helper T-cells, B-cells, killer cells, macrophages, and
cytokines specifically against the thyroid gland (Dayan and Daniels, 1996). These immune cells
then infiltrate into the thyroid gland and induce damage to thyroid follicles, more precisely
follicle cells, size and thereby structure, which in turn interferes with the production of thyroid
hormones, triiodothyronine (T3) and thyroxine (T4). Autoimmune thyroiditis is characterized as
a complex disease due to a strong involvement of genetic and environmental contributors to the
pathogenesis of disease (Burek, 2009). The pathogenesis of autoimmune thyroiditis remains
unclear to this date and the subject of controversy, although there are many animal models
published since the mid-1950s demonstrating autoimmune thyroiditis, with different hypothetical
mechanisms (Nishikawa and Iwasaka, 1999; Rose and Burek, 2000; Kong, 2007).
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The B-cells responsible for the humoral antibody response produce anti-thyroid
antibodies, mainly thyroid peroxidase and thyroglobulin antibodies (TPOAb and TGAb), which
in turn attack the specific thyroid proteins, thyroid peroxidase and thyroglobulin (TPO and TG) in
the thyroid tissue. Although only one aspect of the immune response, in the clinical setting, these
anti-thyroid antibodies are considered to be the bio-markers of the level of the immune response
activity in autoimmune thyroiditis (McLachlan and Rapoport, 1995; Fink and Hintze, 2010).
Usually, these anti-thyroid antibodies are measured from the patient blood serum in order to
evaluate the level of intensity of immune response to the thyroid gland.
Overall, autoimmune thyroiditis induces a slow destruction of the thyroid gland over
many years, which results in the disruption of function of the HPT axis that controls the thyroid
physiology. As a result of this progressive destruction of the thyroid, autoimmune thyroiditis
patients may experience various clinical forms, such as euthyroidism, subclinical or clinical
hypothyroidism and/or hashitoxicosis (transient form characterized as from hypothyroidism to
hyperthyroidism or from hyperthyroidism to hypothyroidism – experienced by some at the onset
of the autoimmune thyroiditis, according to some researchers) (Mazokopakis, 2007) with or
without diffuse goiter (an enlarged thyroid gland).
Autoimmune thyroiditis is more common in women than in men and it can occur at any
age (including, children and adults), but usually shows up in middle-aged women. In 1912,
Hashimoto, a Japanese physician (Hashimoto, 1912), described this disease with hypothyroidism
and goiter (symptom), referred to a classical form. However, some patients do not develop a
goiter but have hypothyroidism – atrophic form; some patients do develop a goiter but switch to
atrophic form as the disease progress over time. Little is known about the connection, if any,
between two forms. Researcher’s suspect that apoptosis (programmed cell death) plays an
important role at the late stage of the disease that causes atrophy (Kotani et al. 1997). Overall, a
complicated phenomenon involved in the course of the disease that makes the size of the thyroid
gland unpredictable.
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Primary Hypothyroidism

Primary hypothyroidism results from the destruction of thyroid gland by autoimmune thyroiditis.
Some people develop this type of hypothyroidism quickly over a few months and some develop it
slowly over several years – this different behavior depends on the aggression of the immune
response to the thyroid gland (Tunbridge et al. 1981; Karmisholt et al. 2011).
Primary hypothyroidism is a graded phenomenon in which the thyroid status changes
from euthyroid (non-diseased) state to subclinical hypothyroidism and may progress to the overt
hypothyroidism state. For this transient situation, TSH values are used to monitor the disease
progression (see Hall and Evered, 1973). We will now give the clinical definitions of subclinical
and overt hypothyroidism based on TSH and free T4 values.
Subclinical (Mild) Hypothyroidism

Elevated blood levels of TSH

and

, but normal free T4

.
Clinical (Overt) Hypothyroidism

Elevated blood levels of TSH

with low free T4

.

Goiter

Goiter means an enlarged thyroid gland. It can be treated by a thyroid hormone replacement,
Levothyroxine (Schmidt et al. 2008). There is no consensus explanation available for the
appearance of goiter in Hashimoto’s thyroiditis, some hypothesize that either that high blood
levels of TSH induce a goiter or inflammation of thyroid gland induce a goiter.
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Hashitoxicosis

Hashitoxicosis is an autoimmune thyroid condition in which the patient experiences transient
hyperthyroid episodes. According to some researchers, Hashitoxicosis is most likely to be
encountered in the early stages of autoimmune (Hashimoto’s) thyroiditis (Mazokopakis, 2007).
Since the chronic immune response is activated against the thyroid gland at early stages
of Hashimoto thyroiditis, the thyroid gland releases its stores of thyroid hormones (both T3 and
T4) and the raw materials for thyroid hormone production into the blood. This sudden burst of
thyroid hormones, especially T3, is responsible for the transient symptoms of hyperthyroidism.

1.5

Clinical Tests

Thyroid function tests are designed to identify the diseased states (hypothyroidism and
hyperthyroidism) from the healthy state of the thyroid gland (Dunlap, 1990). Here, we will
discuss a few tests that are necessary for our study.
TSH Test

Thyroid stimulating hormone (TSH) is measured through the simple blood test by using a modern
method of non-isotope immunometric assay (IMA) with highly enhanced sensitivity and
specificity. The IMA is capable of achieving a functional sensitivity

0.02 mU/L, which is the

necessary sensitivity for detecting the full range of TSH values observed between hypothyroidism
and hyperthyroidism (Baloch et al. 2003). As stated before, the normal reference range for TSH
for adult population is

. If TSH test results in values that are outside

the reference range, then thyroid status is not stable. Suppose thyroid status is stable and
hypothalamic – pituitary function is normal, then serum TSH test is more sensitive and preferred
test than free T4 test (as discussed below) for detecting subclinical (mild) thyroid hormone excess
or deficiency. Therefore, the TSH measurement is considered to be the main tool for the detection
of various degrees of diseased states (such as subclinical hypothyroidism and hyperthyroidism).
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Free T4 Test

Thyroxine (T4) in blood is available in two forms. One is bound T4 and the other free T4. There
is approximately 99.98% bound T4 and 0.02% free T4 in the blood. There are some physical
methods exist to separate free T4 from bound T4 that are equilibrium dialysis, ultra filtration and
gel filtration. Unfortunately, they are technically demanding, inconvenient to use and relatively
expensive for routine clinical laboratory to use. There are other methods that most clinical
laboratories employ, that is, indexes and immunoassay, to get an estimate of free T4. The Index
method requires two separate measurements - one is a total hormone measurement and the other
is an assessment of thyroid binding protein concentration using an immunoassay for thyroxinebinding globulin (TBG) or a T4 uptake test called thyroid hormone binding ratio (THBR) (Baloch
et al. 2003).
Anti-thyroid Antibodies (TPOAb and TGAb) Test

The anti-thyroid antibodies (TPOAb and TGAb) can be measured either by hemagglutination
assay or radioimmunoassay (RIA). The summary of these assays are discussed in (Merrill, 1998).
These methods have been commonly used in thyroid clinics to quantify the anti-thyroid
antibodies.
Ultrasound

Ultrasound can detect thyroiditis because a hypoechoic ultrasound pattern indicates lymphocytic
infiltration (Rosario et al. 2009; Premawardhana et al. 2000). In addition, ultrasound can detect
nodules, lumps, and enlargement of the thyroid gland. In a study of over 3000 prospective
ultrasounds ordered for a variety of reasons, nearly 15% of subjects displayed evidence of
hypoechogenicity.
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1.6

The Operation of the HPT Axis in Hashimoto’s Thyroiditis

The normal function of the HPT axis depends on the function of the hypothalamus, the pituitary,
and the thyroid gland. If something goes wrong with any one of these organs, then the function
of axis is typically interrupted. In our setting, autoimmune thyroiditis destroys the thyroid gland,
which affects the operation of the HPT axis (see Figure 1.4). As a consequence, autoimmune
thyroiditis patients become euthyroid, subclinical, or clinical hypothyroidism with or without
goiter. But, most patients successfully regulate free T4 for several years before they become
hypothyroidism – suggesting that the dynamics of TSH may be interesting in the clinical setting.
Our primary interest here is to track the development of euthyroidism, subclinical or clinical
hypothyroidism with or without goiter, using the measurable quantities in blood, TSH, free T4,
and anti-thyroid antibodies (Ab) along with the other quantity, the functional thyroid size in the
autoimmune thyroiditis. We also want to demonstrate some known and unknown clinical results
using a mathematical model.

Figure 1.4: In autoimmune thyroiditis, there exists a chronic immune response against the thyroid
gland. Due to immune response, the gland’s hormone production may decrease and this cause the
interpretion of the operation of the HPT axis. The dotted lines represent the dormant part of the
HPT axis. The solid line from hypothalamus to pituitary to thyroid gland is the active part of the
axis.
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TSH and Free T4 Relationship

An understanding of the normal relationship between the blood levels of TSH and free T4 is
useful when interpreting thyroid function test results. If TSH measurements are to be used to
evaluate primary thyroid dysfunction (such hypothyroidism/ hyperthyroidism), then it is a
prerequisite that the function of the hypothalamus – pituitary axis is intact. When hypothalamus –
pituitary axis function is normal and thyroid status is stable (meaning free T4 normal), then there
is an inverse log/linear relationship between TSH and free T4 (Spencer et al. 1990). We will show
this log/linear relationship in our dataset and as a consequence of our model later.

1.7

Dataset

We have received a dataset of 119 patients with autoimmune thyroiditis from our clinical
collaborator, Dr. Salvatore Benvenga, Professor of Medicine, Section of Endocrinology,
Department of Clinical and Experimental Medicine, University of Messina, Messina, Sicily, Italy.
This dataset consists of blood serum levels of thyroid stimulating hormone (TSH), free T4 (FT4),
anti-thyroid antibodies (TPOAb and TGAb) and/ or Levothyroxine (L-T4) taken at different time
points for every patient. The unit for time is month. The first measurement of those values for a
patient is considered time zero (month). Half of our patients received treatment with L-T4 from
the first visit to thyroid clinic in Sicily (those patients are referred to treated patients from time
zero). The anti-thyroid antibodies column has missing values for almost all patients. For this
research, we have received Institutional Review Board (IRB) approval from Marquette
University.
To be more specific about the dataset, 46 patients with autoimmune thyroiditis received
no treatment (group1- always untreated, see Figures 1.5 and 1.6) because the levels of free T4
within laboratory reference range, 51 patients with autoimmune thyroiditis received treatment
with L-T4 from time zero (group2- treated patients from time zero, see Figures 1.6 and 1.7) and
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the remaining patients received no treatment initially and then received treatment with L-T4 after
they developed clinical hypothyroidism (group3, see Figures 1.8 and 1.9). For these groups, the
duration of follow-up is varied up to some extent. In group1, the average duration of follow-up is
approximately 24.5 months. In group2, the average duration of follow-up is approximately 32
months. In group3, the average duration of follow-up is approximately 28.5 months. To gain
insight into patient’s progression toward subclinical hypothyroidism or euthyroidism, we pick
patient’s data from group1 (see Figure 1.11(M)). To gain insight into patient’s progression
toward clinical hypothyroidism, we pick patient’s data from group3 (see Figure 1.11(N)). Also,
we separated group3 patient’s data into two parts, before treatment and after treatment in order to
observe the course of the disease (see Figure 1.9). Overall, we observed that patients with
autoimmune thyroiditis showed high variability in developing subclinical or clinical
hypothyroidism. In addition, we observed that the untreated patients mimic the abnormal
function of the axis and treated patients mimic the normal operation of the axis as we expected.
The data was collected from different laboratories across Sicily population under the
approval of government of Italy. These different laboratories had established slightly different
normal reference ranges and set points of the HPT axis according to the local adult population
and the measurements are not comparable. So, in order to utilize the entire data set for analysis, it
is important to scale TSH and FT4 values within the normal reference range adopted for this
project. For that, we introduce a simple proportion formula,

where

are referred to TSH values in the reference interval

respectively and

mU/L

are referred to free T4 values in the reference interval
pg/mL respectively. Note

limit of TSH. Similarly

are referred to lower and upper reference

are referred to lower and upper reference limit of free T4. For an
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example of scaling, see Table 1.1 and 1.2 below. Let us consider a patient (#103) with normal
reference range and measured TSH and free T4 values used in the lab. We will now employ the
above formula to scale TSH and free T4 values into a standard range
pg/mL. Note: For patient 103,

–

mU/L and
.

Table 1.1

Patient ID

Normal

Number

Range

TSH

Standard

TSH

Normal
Range

103

0.35 – 5.5

1.4

0.4 – 2.5

0.8282

103

0.35 – 5.5

1.65

0.4 – 2.5

0.93

103

0.35 – 5.5

2.26

0.4 – 2.5

1.178

Table 1.2

Patient ID

Normal

Free T4

Standard

Free T4

Number

Range

103

7 – 17

13.5

7 – 18

14.15

103

7 – 17

13

7 – 18

13.6

103

7 – 17

11.8

7 – 18

12.28

Normal Range

2d and 3d-Scatter Plots

We use two and three dimensional (2d and 3d) scatter plots to explore the autoimmune thyroiditis
patients dataset. More precisely, for group1 and group3 (untreated) patients, we use 2d and 3d
scatter plots to see the abnormality in the function of the HPT axis, nonlinear relationships
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between clinical variables and inter and intra - variability in developing hypothyroidism. For
group2 patients, we use scatter plots to see the normal operation of the HPT axis.

A

B

Figure 1.5: The figures (A and B) show 45 patients with autoimmune thyroiditis from group1.
Figure A shows all patient’s TSH versus free T4 values taken at different time points. Figure B
shows patient’s log (TSH)(mU/L) versus free T4(pg/mL). All patients have anti-thyroid
antibodies but untreated clinically because free T4 levels are normal. 2d plots show how each
patient is different in the dataset. The solid red lines indicate the reference range of TSH. The
dotted red line indicates the new upper reference limit of TSH. Note: Temporal component is not
shown here.

C

D

Figure 1.6: 3d plots (C and D) show that all patients from group1 have anti-thyroid peroxidase
(TPOAb) and/or anti-thyroglobulin (TGAb) in their blood serum. Group1 patients are monitored
but do not receive L-T4. Figure C shows patient’s free T4 (pg/mL), TPOAb (U/mL) and TSH
(mU/L). Figure D shows patient’s free T4 (pg/mL), TGAb(U/mL) and TSH(mU/L).
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E

F

Figure 1.7: 2d plots (E and F) show treated patients with L-T4 from group2. Group2 contains 51
patients (treated from first visit to thyroid clinic – referred to treated patients from time zero).
Figure E shows patients TSH versus free T4 taken at different time points. Figure F shows
patient’s log (TSH) versus free T4. Comparing Figures F and B, we see that group2 patients has
better inverse log/linear relationship between log (TSH) (mU/L) and FT4(pg/mL) than group1
patients.

G

H

Figure 1.8: 3d plots (G and H) show treated patients from time zero from group2. All treated
patients live with anti-thyroid peroxidase (TPOAb) and/or anti-thyroglobulin (TGAb) in their
blood serum. Figure G shows patient’s free T4 (pg/mL), TPOAb (U/mL) and TSH(mU/L). Figure
H shows patient’s free T4(pg/mL), TGAb(U/mL) and TSH(mU/L).
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I

J

Figure 1.9: 2d plots (I and J) show patients from group3. Group3 contains 22 patients with
autoimmune thyroiditis. Figure I shows how patient’s progress from euthyroidism to
hypothyroidism both in terms of TSH and free T4. Figure J shows the data of 22 patients from
group3 before treatment. All patients in Figure J progress from euthyroidism to hypothyroidism
while free T4 within laboratory reference range adopted for this project.

K

L

Figure 1.10: 3d plots (K and L) show patients from group3. It appears that group3 patients
contain more anti-thyroid peroxidase antibodies rather than anti-thyroglobulin antibodies. Figure
L shows group3 patients with TPOAb(U/mL) taken at different time points. Figure L shows
group3 patients with TGAb(U/mL) taken at different time points.
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M

N

Figure 1.11: 2d plots (M and N) show a patient from group1 and group3. Figure M shows patient
103 from group1 while Figure N shows patient 114 (before treatment) from group3.

Statistical Test for Nonlinearity

We will now investigate an inverse log/linear relationship in our dataset through a statistical test
or model. For that, we first transform TSH values into logarithmic scale, which we call log
(TSH). And then, we will construct a linear regression model to evaluate the relationship
between log (TSH) and free T4. If this model produces a linear relationship, then we conclude
that there is a non-linear relationship between TSH and free T4. For more details such as how to
construct a linear regression model, see (Montgomery et al. 2006). We will use group1 patients
and group3 patients before treatment dataset for this statistical test.
We will employ Matlab curve fit toolbox to construct a linear regression model, and
investigate the statistical quantity R2 which measures the proportion of explained variation in a
dataset. In statistics, R2 is a descriptive measure between 0 and 1. If R2 is close to 1, then the
linear regression model fits the sample dataset better. If R2 is close to 0, then the linear
regression model fits the sample dataset poorly. On the other hand, the population measure, the
Pearson’s correlation

measures the degree of linear relationship between two variables in the

dataset. It ranges between -1 and +1. A correlation of +1 means a perfect positive linear
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relationship between two variables and -1 means a perfect inverse linear relationship. Note is
the estimate of

and the real connection between R2 and

is R2

.

Figure 1.12 shows the linear regression model for group1 patients and group3 patients
before treatment. We found

,

and this implies R2

. Also we

found p-value of t-test < 0.001. Thus, the statistical test confirms a linear relationship between log
TSH and free T4. Hence, TSH and free T4 have a non-linear relationship.

Figure 1.12: The 2d scatter plot showing a linear regression model and the statistical quantities
(R2 and ρ). It seems R2 = 0.3243, (p < 0.001) and Pearson’s correlation
negative.
This indicates that there is a linear relationship between log (TSH) (mU/L) and free T4 (FT4)
(pg/mL). Thus, TSH and free T4 have a non-linear relationship.

1.8

Clinical Staging and Disease Progression

In autoimmune thyroiditis the immunologic attack is very aggressive and destructive and the
pathogenesis of the disease is strongly associated with some suspected genes (for instance, nonMHC class II genes) and environmental factors (for instance, high levels of iodine) (Chistiakov,
2005). Every individual is likely to born with one of the predisposition genes in their body which
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determines whether the individual will develop the clinical states, such as, subclinical or clinical
hypothyroidism or euthyroidism (none) given an environmental stimulus. We will now discuss
patient-specific clinical staging for autoimmune thyroiditis. The staging is important and useful
to plan treatment.
Case1:
Suppose patients with autoimmune thyroiditis (anti-thyroid antibodies are consistently present in
the blood) do not develop any clinical consequences such as subclinical or clinical
hypothyroidism, then the staging will be,
Euthyroidism

Euthyroidism

Case2:
Suppose patients with autoimmune thyroiditis develop subclinical hypothyroidism, then the
staging will be,
Euthyroidism

Subclinical Hypothyroidism

Case3:
Suppose patients with autoimmune thyroiditis develop subclinical hypothyroidism and eventually
become clinical hypothyroidism, then the staging will be,
Euthyroidism

1.9

Subclinical

Clinical Hypothyroidism

Summary

In this chapter, we introduced the background material required for modeling the operation of the
HPT axis in autoimmune thyroiditis. The background material includes thyroid physiology, the
normal operation of hypothalamus-pituitary-thyroid (HPT) axis, autoimmune (Hashimoto)
thyroiditis, and the operation of the HPT axis in autoimmune thyroiditis, clinical tests and clinical
staging. In addition, we discussed autoimmune thyroiditis patient’s dataset used in this thesis.
The dataset was obtained from Sicilian adult population, Italy through our clinical collaborator,
Dr. Benvenga. We separated the dataset into three groups, namely, group1-always untreated
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patients, group2-treated patients with L-T4 (from the first visit to thyroid clinic (time zero)), and
group3-untreated initially but treated after developed hypothyroidism and presented scatter plot
analysis. We observed that group1 and group3 patients showed the abnormal operation of the
HPT axis whereas the group2 patients showed the normal operation of the HPT axis. Finally, we
established patient-specific clinical staging criteria for patients from group1 and group3 in order
to describe their natural history of autoimmune thyroiditis.

CHAPTER 2 – A MATHEMATICAL MODEL OF THE HPT AXIS
We devote this chapter mainly to the construction of a mathematical model of the operation of the
HPT axis in autoimmune (Hashimoto’s) thyroiditis. Recall from the previous Chapter that in
autoimmune thyroiditis the status of the thyroid gland and the normal function of the HPT axis
are interrupted. This model is primarily aimed at the middle - age women or adult patients group
since most of these patients regulate free T4 successfully for several years in spite of an increase
in TSH and the presence of anti-thyroid antibodies (TPOAb and TGAb) in their blood serum. We
will first review other models of the thyroid- pituitary system aimed for regulating free thyroxine
(T4).

2.1

Literature Review

One of the remarkable properties of the thyroid gland is to maintain the amount or concentration
of free T4 within a stable range

. For that, control mechanisms exist within the

thyroid gland. Here, we review some mathematical models from literature describing the
regulation of thyroid hormones. In 1954, Danziger and Elmergreen (Danziger and Elmergreen,
1954) developed a mathematical model based on thyroid and pituitary hormones in order to
explain the mental disorder called periodic relapsing catatonia. They proposed a set of nonlinear
differential equations using Langmuir adsorption isotherm, i.e.,

where

and

are concentrations of TSH and thyroid hormone respectively at time and
are positive real constants. This system of equations describes most of

normal and malfunctions of the thyroid - pituitary system but the system fails to produce the
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sustained oscillations of the hormone levels, which was believed to be the reason for periodic
relapsing catatonia.
In 1956, Danziger and Elmergreen (Danziger and Elmergreen, 1956) proposed another
mathematical model to account for the sustained oscillations of the thyroid hormone levels, in
addition to explaining the normal and abnormal operations of thyroid-pituitary system. They
assumed the pituitary gland secretes TSH, which activates an enzyme in the thyroid gland. The
rate of production of thyroid hormone is considered to be proportional to the concentration of that
enzyme. Their second mathematical model was as follows,

where

and

are concentrations of TSH, an enzyme and thyroid hormone at time . The

system is simply referred to thyroid-pituitary regulator. There are two notable observations from
this model apart from producing sustain oscillations, firstly they linearized the nonlinear terms
and added a third differential equation and secondly, by varying specific model parameters, they
explained the clinical conditions such as hyper - and hypothyroidism.
In 1959, S. Roston (Roston, 1959) presented a mathematical model of endocrinological
homeostasis. The model had no enzymatic reaction terms and periodic solutions but had the
autonomous secretion term for both TSH and thyroid hormones (T3 and T4) from the pituitary
and the thyroid. In addition, he assumed i) thyroid hormones bound to serum proteins such as
(thyroid binding globulin (TBG) and albumin), ii) the physiological volumes Vp , Vx in which
TSH and thyroid hormones are dissolved are constant over a short period of time, and iii) the rate
of secretion of thyroid hormones is proportional to the rate at which TSH passes through the
thyroid gland. A mathematical model of S. Roston was as follows,
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The notable features of this model are all the equations are stated in terms of amounts of TSH
and thyroid hormones, which distributed homogeneously and instantaneously throughout the
physiological volumes Vp , Vx and the parameter k1 represents the sensitivity of the pituitary
gland to thyroid hormones inhibition. Note

is a physiologically standard value of thyroid

hormones (in concentration units). In other words, the effect of the hypothalamus on the secretion
of TSH from pituitary can be expressed by changes in the value of a model parameter (k1).
In 1964, N. Rashevsky (Rashevsky, 1964) published a heterogeneous model of thyroid hormone
regulator in a discussion of a mathematical theory of the effects of cell structure and diffusion
processes on the homeostasis and kinetics of the endocrine system. The author kept all the basic
assumptions of Danziger and Elmergreen (1956) and added the effects of the highly
heterogeneous assumption of thyroid hormone regulator system.
In 1965, Norwich and Reiter (Norwich and Reiter, 1965) published a homogenous model
of thyroid hormone regulation involving a set of linear differential equations expressing the
relationship between the rates of secretion of thyroxine and of TSH. Using their model, they were
able to replicate the known behavior of thyroxine and TSH and made certain predictions which
are amenable to experimental verification or disproval by existing techniques.
In 1968, Joseph J. Distefano and Edwin B. Stear (DiStefano and Stear, 1968) published a
model of thyroid hormone regulation including the hypothalamus. In 1976, P. Saratchandran,
E.R. Carson and J. Reeve (Saratchandran et al. 1976) published an improved mathematical model
of thyroid hormone regulation by the anterior pituitary gland which accounted for experimental
data of TSH and thyroid hormones. In 2008, Mike Degon (Degon et al. 2008) published a
computational model of the human thyroid gland based on the clinical observation of changes in
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the dietary iodine and the molecular-pathways in the thyroid gland. This model captures the
known aspects of thyroid physiology.
In the next section, we construct a nonlinear model of the operation of the HPT axis in
autoimmune thyroiditis. Note that this model is the first mathematical model in the literature to
study the function of the HPT axis with abnormality in the thyroid gland.

2.2

Construction of the model

The model is constructed primarily for patients (especially middle-aged women, or adults) with
autoimmune thyroiditis. To construct a model, we first identify the key players in the disease.
Second, we make assumptions about those key players. Third, we use those assumptions to
construct the rate equations, which is our model. For patients with autoimmune thyroiditis, the
key players are thyroid stimulating hormone, free T4, (unbound) anti-thyroid antibodies and the
functional (active) size of the thyroid gland. Note thyroid stimulating hormone (TSH), free T4
(FT4), anti-thyroid antibodies (Ab) and the functional size of the thyroid gland (T) varies with
time in the presence of autoimmune thyroiditis. Also TSH, FT4 and Ab are measurable quantities
in the clinical setting to diagnose autoimmune thyroiditis but not the functional size of the thyroid
gland (T). The functional size can be computed using other key players which will be discussed
later in this Chapter. We now make the following assumptions,
Assumptions:

1. Anti-thyroid antibodies attack the thyroid follicle cells whereby the gland stimulates
more activity of the immune response.
2. The damaged part of the gland is no longer functional (active) in secreting thyroid
hormones.
3. TSH stimulates the functional (active) part of the thyroid gland for growth and hormonal
secretion.

32
4. TSH disappears from the blood through a non-specific excretion mechanism.
5. TSH distributes uniformly throughout the functional part of the gland.
6. The hypothalamus – pituitary function is intact.
7. The blood concentration of iodine is sufficient for synthesis of hormonal production.
8. The total TSH receptor concentration in the gland is approximately constant since the
anti-thyroid antibodies (TPOAb and TGAb) do not attack the TSH receptors (Tamaki,
1990).
Let us now define the key players in autoimmune thyroiditis in terms of function of time and
followed by the rate equations,
Concentration of thyroid stimulating hormone
Concentration of free thyroxine

at time in blood

at time in blood

the functional size of thyroid gland (active part of the gland)
Concentration of (unbound) anti-thyroid antibodies

at time
at time t in blood

Rate Equation 2.1

The rate of change of concentration of
excretion rate of

is equated to the secretion rate of

minus the

. That is,
21

where

and

are the secretion and excretion rate of

it seems appropriate to include the interaction rate of

respectively. Although,

and the functional size of thyroid gland

on the right hand side of equation (2.1), however we ignore this term by considering the physical
nature of the problem that active areas in the thyroid gland getting smaller and smaller as the
disease progress in the gland.
We will first model the secretion rate with two terms; one accounts for the maximum
secretion rate and another for inhibition rate. That is,
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The term

represents a maximum secretion rate of TSH in the absence of

in the blood

(Utiger, R.D. 1987). The next term represents the inhibition of maximum secretion rate of
depends on plasma concentration of

. It

. This term is modeled by using Michaelis – Menten

kinetics, which made use of a simple mechanism

, and

where

represents the concentration of free T4, free T4 unbound

receptors on the surface of the pituitary gland and/or the hypothalamus (as we remarked before,
we considered the hypothalamus-pituitary gland as one unit for our work (see Figure 1.3)), and
free T4-free T4 receptor bound molecules respectively.
In general, Menten kinetics describes the relationship between the affinity constant (
and total number of receptors (

on the surface of the pituitary gland and/or the hypothalamus

(see (Matthews, 1993)). The affinity constant
required for 50% of maximal

inhibition. Also note that total number of receptors

corresponds to the maximum secretion rate of
Properties of

Since

Then,

Remark

can be described as the concentration of

.
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is at least twice continuously differentiable
Therefore the secretion rate decreases/increases as concentration of
We will now model the excretion rate of

increases/decreases.

. By assuming that the excretion rate of

decreases at a rate proportional to the concentration of

in blood serum (i.e., to say

excrete through non-specific mechanism - assumption 4). Thus, we write

Remark:

Thus,

Rate Equation 2.2

We first derive the rate equation for thyroxine (T4) and then later convert

into free T4 in the

equation using the fact that bound T4 and free T4 are proportional to each other. The rate of
change of concentration of thyroxine
excretion rate of

where

is equated to the secretion rate of

minus the

. That is,

and

represents the secretion and excretion rate of

will first model the secretion rate of

in equation

respectively. We

. To formulate the secretion rate term, we

consider the active region of the thyroid gland (assumption 3). So, let the thyroid functional size
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be

and size of a follicle

(constant). Let the number of follicles be . Let

be the number of

follicle receptors per follicle (constant, assumption 8). Then total number of follicle receptors
is

. Let

and

be the free (unbound) receptors and bound receptors

concentrations. Then
of bound receptors, where

number of unbound receptors and

number

is the volume of the blood. Also, observe that,

Using stoichiometry,

are binding, dissociation and production rate constants affiliated with this reaction.
For this stoichiometry, the rate equations of

and

Furthermore, using on equilibrium assumption on (2.5), we get

Substitute (2.4) into (2.7), we get

That is,

Substitute (2.8) into (2.6), we get

are,
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Thus,

where,

Properties of

Suppose
Since

or

or

, then

or

, then

We will now model the excretion rate of
serum concentration of

for all

in equation

. By assuming that the blood

excreted on the basis of first order kinetics, we get this term,

Thus,

Since physicians measure free T4

to monitor thyroid

autoimmune thyroiditis, we describe (2.9) in terms of
is proportional to free T4

where

is proportionality constant.

We obtain,

. That is,

secretion in patients with

. By utilizing the fact that bound T4
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where

.

Rate Equation 2.3

The rate of change of the functional size (active part) of thyroid gland is equated to the growth
rate minus the destruction rate of functional thyroid gland.

where

and

represent the growth rate and destruction rate of functional

thyroid gland respectively.
We will model the growth rate of the functional thyroid gland using two terms; one
accounting for when
in the blood serum. When

is available in the blood serum and another, when

is not available

is available in the blood serum, we assume that the growth rate is

the proportion of concentration of

in blood serum to total number of receptors in the

functional region.
That is,

Furthermore, we will assume that the total number of receptors in the functional region of the
thyroid gland is directly proportional to the functional size of the gland. That is,

Substitute (2.13) into (2.12), we get,

Now, we let

. Therefore (2.13) becomes,
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When TSH is not available in the blood serum (and from assumption (6)), we assume that the
growth rate of the gland decreases at a physiologically standard constant rate , that is,

Thus, the growth rate of the functional gland is,

where

represents the sensitivity of the thyroid gland to TSH stimulation.

Properties of

does not exist. This implies that there is a singularity at

.

.
We will now model the destruction rate of the functional size of the thyroid gland. The
destruction rate of the functional thyroid gland depends on the aggression of the anti-thyroid
immune response. To model this term, we use anti-thyroid antibodies (TPOAb and TGAb) to
stand in for immune response (assumption 1) and the functional size (T) for the active part of the
gland. Therefore, the destruction rate of Ab is assumed to be the interaction rate of anti-thyroid
antibodies and the functional size of the gland. So, we write

Properties of

if

or

then

.

The rate equation of the functional size of the thyroid gland is,
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Rate Equation 2.4

The rate of change of concentration of unbound anti-thyroid antibodies is equated to the
production rate of anti-thyroid antibodies due to the destruction of the functional size of thyroid
gland minus the aging rate of anti-thyroid antibodies respectively. That is,

where

and

represents the production rate of anti-thyroid antibodies due to the

destruction of the functional size of thyroid gland and the aging rate of anti-thyroid antibodies
respectively. We will model the production rate of anti-thyroid antibodies using the interaction
term, that is,

[Note – this is an important point in defining Hashimoto’s as

an autoimmune disease, because it reflects our assumption 1 that anti-thyroid immune response
attacks the thyroid follicle cells whereby the gland stimulates more activity of the immune
response and that antibody acts as a marker of immune activity]. We will model the aging term
using the first order kinetics, that is, anti-thyroid antibodies concentration decreases at a rate
proportional to the levels of anti-thyroid antibodies in the blood (

).

Thus,

Hence, the four dimensional model (4d) is as follows,
(2.2)

(2.10)

(2.15)

(2.17)
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with initial conditions associated with the model and the parameters are all positive, that is,
. The equations (2.2), (2.10), (2.15) and (2.17) will be
referred to as (2.2) – (2.17).
Remark
–

The right hand sides of the model
local Lipschitz condition in

are continuous except when

and satisfy a

.

Existence and Uniqueness Theorem

We will now state the general theorem of existence and uniqueness for the initial value problem
(Robinson, 2004, page 71).
Theorem
Consider the differential equation

where

is a point in

continuous for

and

is a vector field in

in some open set U in

Then there exists a solution

, and that

. Assume that both

defined for some time interval –

are two such

be this unique solution with

depends continuously on the initial condition

T > 0 be a time for which

is defined for

distance between solutions. Then, there exists a
allowable initial conditions, such that if
and

and

such that

then they must be equal on the largest interval of time about

where both solutions are defined. Let
The solution

are

is a point in U.

. Moreover, the solution is unique in the sense that if
solutions with

and

. Let

. Moreover, let
be any bound on the

which measures the distance between
then

is defined for

.
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for

. In fact, the solution

is differentiable on the initial condition,

.

Proof: see (Robinson, 2004, page 86 - 89)

Let us now compare the necessary assumptions needed for the existence and uniqueness
theorem to satisfy in our 4d model. In our model, we have,

and

Note

and

are a continuous functions except possibly when

Thus, we require a non-negative open region in

without

.

in order for the existence and

uniqueness theorem to work in our 4d model and of course all the initial conditions are nonnegative,

contained within the open set

.

We will now employ the model in an adult population, since they are the ones who
develop this autoimmune thyroiditis most frequently. For a given adult group, the clinical
variable normal values, ranges, units and sources are listed in Table 2.1. Note that the normal
value of TSH, FT4 and the functional size varies with person to person. So, we arbitrarily picked
normal values from the reference ranges adopted for this dissertation. The normal value of antithyroid antibodies is zero.

Table 2.1: Variable Normal Values, Ranges, Units and Sources

Name

Normal
Value
1
13
0.015
0

Normal Range
–

Source
Literature(Baloch et al. 2003)
Literature(Baloch et al. 2003)
Literature(Carle et al. 2009)
Dataset

Unit
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2.3

Singularly Perturbed Structure to 4d Model

We have observed that thyroid stimulating hormone (TSH) changes on the order of days in the
blood, free T4 (FT4) changes on the order of weeks in the blood, and the functional size of
thyroid gland (T) and anti-thyroid antibodies (Ab) changes either on the order of weeks or years,
possibly depending on the person, the degree of the disease, age, gender, race and so many
unknown factors. Thus, there exists at least two different time-scales in the model. We impose
this assumption of two time-scales present in our 4d model. We will call TSH a fast state
variable since it changes on the faster time scale and the rest of the variables (FT4, T, and Ab) are
slow state variables since they change on the slower (common) time scale. This in turn gives rise
to a singularly perturbed structure to our model and also helps us to analyze the model effectively
by reducing a dimension (see below for the introduction of singularly perturbed initial value
problem). The presence of this structure is seen in Chapter1 in the log-linear relationship
between TSH and free T4.
Divide (2.2) with

, then we get,
(2.18)

(2.19)

(2.20)

(2.21)
Let

Then, we obtain a singularly perturbed structure of our 4d model,
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Note: the singularly perturbed model equations numbers are all renamed ((2.18) – (2.21)). The
singularly perturbed 4d model is described on the order of intermediate slower time scale, more
precisely, in terms of weeks (see parameter estimation section in Chapter 4). Also, we could have
chosen

to define instead of

. If

was our chosen candidate, the singularly perturbed

model will be on the order of years (slower time scale).
Introduction to Singularly Perturbed Initial Value Problem

Let

denote the “slow” variables and

denote the “fast” variables, then standard autonomous

singularly perturbed initial value problems are given as,

where a real parameter near a zero and

and

. Because of the presence of

fast and slow states in the model, singular perturbation problem shows multi-time-scale behavior;
therefore it is reasonable to analyze the slow and fast state variables on the order of different time
scales. The original model breaks down into two related sub models, the reduced and boundary
layer models. We will now show this analysis (see Tihonov, 1952; Hoppensteadt, 1966, and
1971).
First, by setting

, we see that the dimensions of state equations reduce from

to . Thus, the differential equation (2.22) will change to:
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after dropping the initial condition

. We call problem (2.23) the reduced model.

Second, by introducing the stretching transformation

Furthermore, by setting
solution. We will now let

yields

to the problem (2.22) results in,

which in turn results in

, a constant

to obtain the following differential equation,

We call problem (2.25) the boundary layer model. Thus, in summary, analysis of a
singularly perturbed initial value problem involves two sub models: the reduced model, and the
boundary layer model. The former is related to dynamics of the slow variables while the latter
model reveals the dynamics of the fast variables where

becomes constant.

For our work, we focus on the reduced model of the singularly perturbed initial value
problem. Thus, we will now discuss an important theorem of Hoppensteadt (applied to
autonomous system), where he proved that the solution of singularly perturbed model for small
approximates the solution of the reduced model on the time interval
conditions on the functions

if certain

are satisfied.

Hoppensteadt Theorem (Hoppensteadt, 1966)

Preliminaries:
Norm of a vector: (required to measure the distances between the solutions of the system)
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Let

such that

represent the restriction of

to

and let
and

and

respectively. Let us assume that

and

satisfy the

following conditions.
1) The reduced model (2.23) has a solution

for all time

2) The functions
components

. Here
,

and similarly for

and

.

denotes the matrix with
.

3) There exists a bounded, twice continuously differentiable function
for all
and

. Furthermore assume
for some

such that

is isolated in the sense that if

imply

.

With this assumption, the reduced model can be written in the more convenient form

4) The function

is continuous at

uniformly in

and

and

uniformly asymptotically stable solution. In this assumption, Hoppensteadt
translated the equilibrium to the origin, but it can be applied to any equilibrium.
5) The function

is continuous at

uniformly in

derivatives with respect to and the components of
6) Let

any

and its

are bounded on

.

be the class of all continuous, strictly increasing, real-valued functions
with

; and let

be the class of all nonnegative, strictly decreasing,

continuous, real-valued functions
asymptotically stable. That is, if
and

and

,

. Let the zero solution of
is the solution of

such that

for

is

, there exist
and

.

Theorem:
Let the conditions (1) through (6) be satisfied. Then for sufficiently small
the solution of the original model exists for
the reduced model as

and

and this solution converges to the solution of

uniformly on all closed subsets of

.

Remark
If we remove the uniform condition from (4) and replace

by

Hoppensteadt theorem, we obtain a similar theorem from Tikhonov (1952).

from
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Now, from

, we have a reduced model,

Since the algebraic equation has a unique root,

, so we can write our model in

the more convenient form,
(2.26)

(2.27)

(2.28)
The reduced model, (2.26) – (2.28) defines the vector field on the algebraic surface, also called
slow manifold
surface

. So, the solution of the reduced model stays on the
. We will use the reduced model in Chapter 4 for the stability

analysis and the numerical simulations.

2.4

Summary

This chapter focused on the construction of a nonlinear model of the operation of the HPT axis in
autoimmune (Hashimoto’s) thyroiditis. Followed by the construction of the model, we stated and
compared the existence and uniqueness theorem in non-negative region of four dimensional
spaces. For this thesis, we chose an adult population and listed their normal values, ranges, units
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and sources in a tabular format for all model variables, since patients with autoimmune thyroiditis
are normally from adult populations rather than other populations. The model contains eleven
parameters and four initial conditions. The model has singularly perturbed structure to it since the
system has at least two different time scales, which in turn enables one to reduce a dimension of
the 4d model.

CHAPTER 3 – NORMAL AXIS OPERATION
In the previous chapter, we formulated a model which encompasses both normal and abnormal
operation of the HPT axis. In this chapter, we will look at the normal operation of the HPT axis
operation. For that, we assume there are no anti-thyroid antibodies in the system. This can be
done by setting the initial condition (state) of anti-thyroid antibodies to be zero in the singularly
perturbed model in Chapter 2, solutions starting with

will always have

.

Thus, the four dimensional (4d) singularly perturbed model becomes a 3d model. The 3d model
is,

(2.29)

(2.30)

(2.31)

3.1

Mathematical Analysis of the Singularly Perturbed (3d) Model

Remark

the 3d initial value problem has a unique solution if
Chapter 2).
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(see
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Steady states

For any

, one can solve for steady states by setting the right hand sides of each equation in

the model,
polynomial for

equal to zero. If we now solve for steady states which yields, a cubic
suggesting that the model could predict three meaningful steady states.

In Appendix B, we applied Descartes’ sign rule to the cubic polynomial and noticed that the cubic
polynomial has one sign change and so therefore, the model has exactly one positive real steady
state and other two steady states are either negative real or complex depending upon the model
parameter values. The existence of positive real steady state is a biologically meaningful state;
we call this steady state the euthyroid state. The existence of other two steady states either in the
negative orthant or complex space is biologically meaningless. For steady state analysis, we only
consider the euthyroid state which is as follows (see Appendix B for solving the cubic
polynomial),
Let

Then
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Note: the euthyroid state depends on the model parameter values suggesting that this state is
unique for each individual in the adult population. Also, the euthyroid state is independent of the
parameter

.

Let

Then for

We have the following theorem.
Theorem 3.1 (Boundedness)

The solutions of

with initial conditions in

are bounded for all

Proof

First, let us determine six faces,
in
and

where,

such that the faces trap solutions within a rectangular box

the unit outward normal vector to . The 3d rectangular box is

represented as follows,

Second, let
On

and
,

be the unit normal vectors in the positive
and

requires

directions.

.
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Along the edge

and

on edge
is determined by

since

for any solution of

and

. So the sign of the second derivative of

on that edge.

and

. Thus,

and

edge. So the solution would move back into
On

,

Along the edge

So the sign depends on

on that edge,

and

increases on that

.

requires

and

. On

for any solution of

and

on that edge,
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Thus

and

decreases on that edge. So the solution would move back into

.
Therefore, the faces

and

Consider now the faces
On

,

, where

and

and

, where

requires

if and only if,

We can now obtain the lower bound for

On

,

and

by choosing

as,

requires

if and only if,

We can now obtain the upper bound for

Therefore, the faces

by choosing

and

as,

where

.
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Finally let us consider the faces
and

Along the edge

and

. On

for any solution of

. On the edge

This is equal to zero if, in addition

and

where

,

requires

So the sign is determined by

the range

and

on that edge,

and

, otherwise

,

, so

is increasing back into

except in one case. To examine the remaining case, if
, as

and

. We look at
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So the sign of

is determined by

and

and

at that point this means that
,

and

at

.

From the previous case,

On

. Consider the second derivative of

on

and

is increasing back into the range

. So
.

requires

On the edge

,

From the previous work,

when

, except when

. Examining

that case,

Again from a previous case, we found
and as a result,
Therefore, the faces

Thus,

is decreasing at the point back into the range
and

where

.
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Hence the proof

Corollary

As

in

is compact and invariant, there will be a steady state in

(Srzednicki, 1985). Since

lies in the positive region and there is only one steady state in the positive region, it must be in
.
Before we begin the analysis of the 3d model
reduced model by setting

, we will analyze the

to gain insight into the dynamics on the algebraic surface
.

3.2

Mathematical Analysis of the Reduced (2d) Model

Let us consider the reduced model from

Notice that the reduced (2d) model describes its dynamics on the algebraic surface (also called
slow manifold for the reduced model in the literature of singular perturbation theory), , which is
as follows,

One could imagine

(2d manifold) embedded in 3d space for equal to zero. Thus, we will first

start with the mathematical (phase plane) analysis of (3.1) – (3.2) in the bounded region
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contained on the algebraic surface,

and second, we will present the numerical

simulations of the reduced model to support the analysis.
Qualitative Behavior of the Trajectories

Here, we are concerned about the qualitative behavior of the trajectories with initial conditions
within the bounded region

. We will first start with an array of mathematical definitions

that are required to construct trajectories within

.

Consider the autonomous initial value problem,

where
field in

is continuously differentiable function and

as a vector

.

Definition: Forward trajectory

The forward trajectory through

where

is the set

is the unique solution with initial condition

(see Chapter2 for general

construction of ).
Definition: Positively Invariant Set

A set

is said to be a positively invariant set if

then

Definition:

The

of

is
.
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Definition: Stable Manifold

For an equilibrium state

, the stable manifold of the equilibrium state is given by

Before we use all the above definitions; we will do linear stability analysis of the euthyroid state.
Linear Stability Analysis

This section is concerned with the stability of an equilibrium (euthyroid) state for the system (3.1)
– (3.2). First, note that the euthyroid steady state stays on the slow manifold within the bounded
region

. Second, we will test the local and global nature of this state on the slow manifold

using the reduced system. Recall again from Chapter 2, the reduced system defines the vector
field only on the slow manifold.
Consider the reduced system,

Lemma 3.1

The euthyroid state

of

is locally asymptotically stable on the slow

manifold.
Proof
We linearize the model,
at a general point

near the euthyroid state
is,

. The Jacobian matrix
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Evaluating the Jacobian at

, we get

Thus, the linearized system can be written as,

Observe that,

and

Thus, the linear system is asymptotically stable. Hence the euthyroid state
asymptotically stable. Furthermore, since the eigenvalues of matrix
the characteristic equation

and the roots are

We have three cases,
Case1:

is locally
are the roots of
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Suppose

, then the eigenvalues of are real. However,

Thus, the euthyroid state is a stable node.
Case2:
Suppose

, then the eigenvalues of are complex with negative real part,

therefore the euthyroid state is a stable focus.
Case3
Suppose

then the eigenvalues of are equal with negative real part

therefore the euthyroid state is a degenerate stable node.
Remark

For our system,

We call the left hand side as

for simplicity. For illustration, we use

parameter values from Table A2 (see Appendix A – parameter estimation) except for
then,
, then

. If

and then the euthyroid state is a stable node. If

, and then the euthyroid state is a stable focus. If

or

,

is approximately zero, therefore the euthyroid state is a degenerated stable node (see Figure 3.1).
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Figure 3.1: For the values in Table A2, but with
varying, the figure shows how changes the
changes the nature of the euthyroid steady state. Note that the euthyroid state is independent of
.

Basin of Attraction for the Euthyroid State

In this section, we will show that the euthyroid state is an attractor for the set of points on the
slow manifold. We show this by employing Dulac’s Criterion and the Poincare - Bendixson
theorem on the slow manifold. Recall that the euthyroid state is located within the bounded
region,

.

Dulac’s Criterion (Robinson, 2004)
This method is based on Green’s theorem, which rules out the possibility of closed orbit in the
planar region. This method works only in 2d space (manifold). In our case, the planar region is
the algebraic surface (slow manifold) and the reduced (2d) model
points on the slow manifold.

is defined at all
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Theorem: (Dulac’s Criterion)

Consider the differential equation

where

be a continuously

differentiable vector field defined on simply connected subset
a continuously differentiable, real-valued function

in the plane. If there exists

such that

has one sign throughout , then there are no closed orbits
lying entirely in .
Theorem (Poincare-Bendixson) (Robinson, 2004)

Consider a differential equation

on

a forward trajectory

is bounded. Then

or

. Assume that

is defined on all of
either

. Assume that

contains a steady state

is a periodic orbit.

Remark

Let

and

be two open sets in

. A homeomorphism

onto , which has a continuous inverse
then

from

to

from

to

. It follows that

is a continuous map
is one to one (i.e., if

.

Remark
We will first use Dulac’s criterion to rule out the possibility of closed orbit in the bounded region
on the slow manifold and next, by using the Poincare-Bendixson theorem (on the slow manifold),
we conclude all trajectories of the system

–

converge to the euthyroid state.

Lemma 3.2

The euthyroid state
points

of the reduced system

contained in the slow manifold

.

is an attractor for the set of
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Proof

Let

and

. We already have constructed the bounded region

(slow

manifold) for our reduced (2d) model.

This implies there are no closed orbits in the bounded region
the bounded region

(slow manifold). Since

is compact and positive invariant, therefore, we conclude from the

Poincare-Bendixson theorem that all trajectories of the system

–

converge to the

euthyroid steady state.

Theorem 3.2

For any given initial condition

in

is on the slow manifold, there exists a

unique trajectory starting at the initial state which approaches the euthyroid steady
state

as

. That is,

Proof

We have shown in Theorem 3.1,

is a bounded region, so

manifold. This means any trajectories of reduced (2d) model
time

will stay there for all future time

orbits in

is a bounded region on the slow
–

starting in

and we have also shown that there are no closed

but the euthyroid state by using Dulac’s criterion. From Lemma 3.1, and 3.2, we

see that the euthyroid state is locally asymptotically stable and attracts all trajectories starting
in

at

. Thus,

63

Theorem 3.3

For any

and initial condition

, there exists a unique

trajectory starting at the initial state which approaches to the euthyroid state
in .
That is,

Proof

We prove this theorem by relating the trajectories of the reduced (2d) model
the 3d model

and

through the Hoppensteadt theorem (see Chapter 2). Hoppensteadt’s

theorem says that for sufficiently small

and initial condition

, the trajectory of the 3d model
to the trajectory of the reduced 2d model
of

–

. Note: in our case,

exists for
–

as

in
and that trajectory converges

uniformly on all closed subsets

is a fixed small number and does not converge

to zero, so the trajectories of the 3d model and 2d model do not converge. But, the
, must be the euthyroid steady state for both the reduced (2d) and 3d model (see Figure
3.9). This means that the distance between the trajectories of the reduced (2d) model and the 3d
model in

must be decreasing in order to share the same

. In addition,

is

positively invariant and contains the euthyroid steady state which is locally asymptotically stable
(see Chapter 4). Thus, our result follows

3.3

.

Numerical Simulations of the Reduced (2d) Model

We have done the mathematical analysis of the two dimensional reduced system in the bounded
region on the slow manifold. In this section, we will present the numerical simulations of the
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reduced 2d model to confirm our mathematical analysis (see Figures 3.2, 3.3, 3.4, 3.5, 3.6 and
3.7). For numerical simulations, we pick an imaginary normal individual, whose normal

,

free T4 and the functional size are given in Table A1, in other words, euthyroid state of this
individual is given in Table A1(see Appendix A). For this individual, the parameter values are
estimated and listed in Table A2 (see Appendix A) however, we use

in

order to confirm our analysis. We start the 2d system with different clinical initial states and
investigate the dynamics of our imaginary individual. For all our simulations, we use ode15s
solver from Matlab suite (see Chapter 4 for specific details).

Figure 3.2: The plot of free T4 and the thyroid functional size
as a function of time of a
simulated individual. Note the thyroid functional size
is in milliliters. We start the reduced
(2d) model at the initial state
, having free T4 and within the
reference range (normal), and using parameter values from the Table A2 in Appendix A except
for . Here
. The 2d reduced system predicts that the imaginary
individual probably develops a goiter before the monitored values asymptotically approaches the
euthyroid state
in approximately 60 days.
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Figure 3.3: The phase plane view of the previous time series plot. Note the thyroid functional
size
is in milliliters. Here
. The reduced 2d system
asymptotically approaches the euthyroid state
.

Figure 3.4: Note the thyroid functional size
is in milliliters. We start the reduced (2d) model
at the initial state
, having free T4 above the upper reference limit
of free T4 and T normal (hashitoxicosis), and using parameter values from the Table A2 in
Appendix A except for . Here
. The 2d reduced system predicts
that the imaginary individual asymptotically approaches the euthyroid state
in
approximately 60 days.
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Figure 3.5: The phase plane view of Figure 3.4. Note the thyroid functional size
is in
milliliters and
. The reduced 2d system asymptotically approaches
the euthyroid state
from hashitoxicosis state
.

Figure 3.6: Note the thyroid functional size
is in milliliters. We start the reduced (2d) model
at the initial state
, having free T4 below lower reference limit of
free T4 and T normal (clinical hypothyroidism), and using parameter values from the Table A2 in
Appendix A except for . Here
. The 2d reduced system predicts
that the imaginary individual asymptotically approaches the euthyroid state
in
approximately 60 days.
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Figure 3.7: The phase plane view of Figure 3.6. Note the thyroid functional size
is in
milliliters and
. The reduced 2d system asymptotically approaches
the euthyroid state
from clinical hypothyroidism state
.

3.4

Numerical Simulations of the Singularly Perturbed (3d) Model

To present numerical simulations of the 3d model, we will use the original 4d model, (2.2) –
(2.17) by setting the initial condition of anti-thyroid antibodies to be zero (that is,

). We

use ode15s from Matlab suite for all our simulations (see Chapter 4 for specific details). We
illustrate the mathematical analysis of the 3d model through our simulations. For that, we use our
imaginary individual’s variable and parameter values from Table A1 and Table A2 in Appendix
A. Also, we use

.
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Figure 3.8: Note the thyroid functional size
is in milliliters. We start the original (4d) model at
the initial state
, having TSH, free T4 outside
the reference range (clinical hypothyroidism), T and Ab normal, plus using the parameter values
from Table A2 in Appendix A except for . Here
. The 4d
system predicts that the imaginary individual asymptotically approaches the euthyroid
state
in approximately 60 days. Also, observe that TSH quickly
approaches the euthyroid state suggestive of the existence of a fast-time-scale for TSH.

Figure 3.9: 3d phase space view of Figure 3.8. Note the thyroid functional size
is in milliliters
and
. The reduced 2d system asymptotically approaches the
euthyroid state
from clinical hypothyroidism state
. Using the
algebraic equation,
,
is computed for the 2d system. The 4d system asymptotically
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approaches the euthyroid state

from clinical hypothyroidism state

. Note: the reduced 2d system approximates the 4d system. Also,
is a small fixed value.

3.5

Summary

This chapter focused on the dynamics of the normal operation of the HPT axis. For that, we have
excluded the anti-thyroid antibodies (stand in for anti-thyroid immune response) from the system
which gave rise to the 3d model. We used the singularly perturbed 3d model in order to reduce a
dimension of the 3d model and to study the dynamics of the HPT axis on the algebraic surface
(plane) in an effective manner. Thus, the reduced 2d model described all its dynamics in the
plane, in fact, the algebraic surface (also called slow manifold). In addition, we constructed a
bounded region in the slow manifold so that if a solution starts within the bounded region at
time

, it stays there for all future time

. Finally, we proved that the euthyroid state is

locally asymptotically stable on the algebraic surface and an attractor for the set of values in the
bounded region (D). This is the main result for this Chapter. We have also presented numerical
simulations of reduced 2d model
the mathematical analysis of this Chapter.

and original 4d model,

–

to confirm

CHAPTER 4 – ANALYSIS OF DYNAMICS OF 4d MODEL
In this chapter, we present an analysis of the full 4d model which includes investigating the local
stability of euthyroid state and diseased steady state. Along with this, we present numerical
simulations to support stability analysis of the full 4d model. In addition, we present bifurcation
analysis to determine the qualitative behavior of the system, that is, the structural stability of the
model as a parameter changes in the system.
The 4d model is as follows,

Remark

Note that the 4d initial value problem has unique solutions if
(see Chapter 2).
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4.1

Mathematical Analysis of the Singularly Perturbed (4d) Model

We begin the analysis of 4d model by examining the steady states of the system. For every

,

we can find equilibrium states. Setting the left hand side of (2.21) equal to zero yields
or

. When

, we obtain the euthyroid state (steady state – see Chapter 3 and

Appendix B), that is,

Let

Then

The euthyroid state is located in a hyper plane (

, reasonable initial conditions for the

system of differential equations are
in numerical simulations to investigate the local stability of
euthyroid state in patients with autoimmune thyroiditis.
Next, consider a possible equilibrium when

. This requires

substitution of this equilibrium value into the right hand sides of the equation
, that leads to a steady state in the system, which we call a diseased state,

and
,

and
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Remark

If the expression

is true, then the diseased (steady) state is located in the

negative orthant, that is,

.

Positively Invariant (Bounded) Region

We constructed a bounded region in the previous chapter using
state of anti-thyroid antibodies is set to zero

,

and

when the initial

. But, now we will establish a bounded

region in 4d space for the full model when the initial state of anti-thyroid antibodies is not set to
zero. Recall the definitions of
of the rectangular box .
Let

.
Then for

and

from the previous chapter – the particular faces

73

Theorem 4.1

If

–

, the solutions of

all time

that start in

at

will remain in

for

.

Proof

We construct eight hyper planes in
and

where,

faces of the box

such that the planes trap solutions within a rectangular box

the unit outward normal vector to

on seven of the hyper plane

. That is,

In autoimmune thyroiditis, we can choose the lower bound for anti-thyroid antibodies
is,

(the hyper plane). If a trajectory reaches

, that

, then an argument similar to that in

Chapter 3 where shows the trajectory stays within the following box,

where
and

. Second, let

, and l be the unit normal vectors in the positive

directions. In the third case, we established bounds for

the lower bound for

is affected in the presence of anti-thyroid antibodies (

Thus, we construct a new lower bound for
On

,

if and only if

, and

and

requires

and upper bound for

,

in Chapter 3, but
) in the system.
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By choosing

(minimum value) and

(maximum value), we can obtain

the lower bound for , that is,

But, note that solutions on the edge,

have

So, along the edge,

for any solution of

–

on that edge,

So the sign

is determined by

. On that edge

, and
. For

Therefore, when
range

and

,

. We see

if

, otherwise

, suppose

and

and

and

,

is increasing back into the

. Thus,

Consider now the hyper plane

where

.

for
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On

,

and

requires

if and only if,

By choosing

(maximum value), we know for sure that the anti-thyroid antibodies

(Ab) are bounded as long as the following inequality satisfies,

Thus, we conclude that

.

Hence the proof

Corollary

As

in

is compact and invariant, there will be a steady state in

(Srzednicki, 1985). Since

lies in the positive region and there is only one steady state (euthyroid state) in the positive
region, it must be in
expression

. Also, the diseased state is not in the positive region as long as the
is true. Thus, the model suggests that the necessary condition for

the diseased steady state to emerge into the positive region, in fact in the box, is
. In addition, we observed that necessary condition becomes true as

(positive parameter)

changes in the system (see bifurcation analysis below).
Theorem 4.2

When

there is only one steady state (euthyroid state) in the positive octant.
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Proof

The proof of this theorem follows from the following definition which relates the euthyroid state
and diseased steady state.
Definition
When
has

Let

–

, the second steady state (diseased state) of the system
. So it must coincide with the euthyroid state in the positive quadrant if

be the unique value of

where,

In addition, we have observed

,

Note: This critical parameter can be uniquely determined for every individual in the adult
population.
Remark

is independent of the parameters

because the euthyroid state is independent of those

parameters.
Local Stability of Euthyroid State

To prove the euthyroid state is locally stable in 4d space. We need Lemma 4.1.
Lemma 4.1

Let
inequality)

be real roots of

. If

then

(quadratic

77
Proof

Since
If

,
, both

and

then

.

Theorem 4.3

The euthyroid state is locally asymptotically stable in

–

if

where

Proof

We will prove this theorem by using the Routh-Hurwitz criteria on our 4d model. We first state
the Routh-Hurwitz theorem, along with the stability condition for 3d case and then prove our
claim.
Routh-Hurwitz Theorem (see Hurwitz, 1895; Routh, 1877; Edelstein-Keshet, 1988)

Given a characteristic polynomial
follows:

, define

matrices as
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where the

term in the matrix

is

Then the real parts of the roots are negative if and only if the determinants of all Hurwitz matrices
are positive:

May (1973) summarizes these conditions for the cases
will use the case

. For our problem, we

, which is as follows,

Let us now consider the Jacobian matrix of full 4d model of (2.18) – (2.21) at euthyroid state
1






k3 kd T1

2
 (kd  TSH1 )

k5

T1


0


By utilizing
becomes,

and evaluating

k1ka
 k2 (ka  FT 41 )2

0

 k4

k3TSH1
(kd  TSH1 )

0
0



k5TSH1
 k6 Ab1
T12
k7 Ab1





0



k6T1 

k7T1  k8 
0

, then the Jacobian
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 k2



k3 kd T1

2
 (kd  TSH1 )

k5

T1


0


k22TSH12
k1ka

0

-k4

k3TSH1
(kd  TSH1 )

0
0

-

k5 N
T1
0





0 


-k6T1 

k7T1 - k8 
0

For this Jacobian matrix, the eigenvalues can be found by solving the characteristic
equation

. Note that the euthyroid state is asymptotically stable if and only if all

the eigenvalues of Jacobian matrix have negative real parts. For this Jacobian matrix, the
characteristic equation is,

We can immediately see that if

then one of the eigenvalues

has negative real part and clearly if

is a zero eigenvalue in the direction of anti-thyroid antibodies.
Let us now consider the equation in the square bracket,

Rewriting the above,

where

, there
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Substituting

,

Note that

and

is located in non-negative orthant

since all the parameters are positive and the euthyroid state
. By Routh-Hurwitz condition, the remaining three roots of

characteristic equation will have negative real parts if and only if

Clearly

are true, since all parameters are nonnegative. We will now examine

the condition

Divide by

. Consider,

,
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We want

. By Lemma 4.1, this inequality becomes true if

where

Hence the proof

Remark

For the given parameters values in Table A2, we see that the above inequality
and thus

is satisfied

.

Observation

If

and inequality

negative real parts. If

are true, then all four eigenvalues of euthyroid state have
but inequality

is true, then the eigenvalue of euthyroid state

in anti-thyroid antibodies (Ab) direction becomes zero. Therefore, the euthyroid steady state loses
its stability to the diseased steady state. In fact, in general, when

the euthyroid and

diseased states merge with each other and exchange stability in the direction of anti-thyroid
antibodies (see bifurcation analysis section below). Thus, there is a bifurcation at

, but

we do not know exactly what kind of bifurcation it is at this point.
If

but inequality

holds, then the eigenvalue of euthyroid state in anti-

thyroid antibodies direction will have positive real part and the other eigenvalues of euthyroid
state have negative real parts and therefore the euthyroid state becomes unstable only in the
direction of anti-thyroid antibodies. Thus, we conclude that

is a bifurcation parameter for the

euthyroid steady state. Next, we will study the local stability of the diseased state for

.
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4.2

Mathematical Analysis of the Reduced (3d) Model

Recall that, for
emerge into the box
in fact in

, the necessary condition

for the diseased steady state

becomes true. Thus, we have a diseased state in the positive orthant,

,

. We will use Routh – Hurwitz criterion to study the local stability of the diseased

state. But, for this, we will use the reduced model from singularly perturbed 4d system – since
we focus on the operation of the HPT axis in autoimmune thyroiditis and the active part of the
axis (the hypothalamus-pituitary function is intact) let us reduce a dimension of the 4d model (see
Chapter 2). Thus, the reduced (3d) model defines the problem of interest and of course we
assumed that is zero, although it is

. Note that the reduced (3d) model is the

approximation of the singularly perturbed 4d model in a slower time scale. By setting

, we

obtained the reduced (3d) model (see Chapter 2), which is as follows,
(2.26)

(2.27)

(2.28)
Notice that the reduced model describes all its dynamics on the algebraic surface (slow manifold).
We will call this slow manifold as

One could imagine
and 4.4).

, that is,

(3d manifold) embedded in 4d space for equal to zero (see Figure 4.3
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Theorem 4.4

If

, the necessary condition

and then the diseased state in system

for the diseased state in
–

becomes true

is locally asymptotically stable.

Proof

We will now apply Routh-Hurwitz criteria and analyze the local stability of the diseased state. As
a first step, let us compute the Jacobian matrix at the diseased state, which is,

Evaluate

with

becomes

Substituting

,

, and

,then the Jacobian
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Remark
If

then

.

The eigenvalues of the diseased state can be found by solving the characteristic
equation

, which is,

where,

. We will now check May’s remaining

Since
condition

.
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Notice that

Therefore, the condition

is true for any given a set

of positive model parameter values and thus the diseased state is always locally asymptotically
stable once it appears in the positive orthant.

4.3

Numerical Simulations

The numerical simulations of the four dimensional (4d) system results in trajectories in 4d state
space (actually 5d with time). In order to visualize the trajectories of the 4d system, when
plotting we suppress time and the results of two or more of the four variables. For numerical
simulations, we will use the original 4d system
singularly perturbed system

–

–

, unless there is a need to use the

or the reduced system

–

.
(2.2)

(2.10)
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(2.15)

(2.17)
–

Since the system

contains two different time scales, the Runge - Kutta

methods such as ode23, ode45 in Matlab suite may not be the best choice for numerical
approximations. Recall from Chapter 2 that the two-time scale issue was due to the presence of
fast and slow variables in the 4d system. This means that a portion of the trajectory varies rapidly
and the remaining portion of the trajectory varies slowly in 4d state space. Also, if we use the
singularly perturbed system

–

for simulations in Matlab, again Runge-Kutta

methods do not work well since it contains a small parameter
. These systems

–

and

–

in front of the derivative of

are referred to stiff systems in the

numerical analysis literature. Therefore, we will now introduce the concept of stiff systems, the
definition of stiffness, and a possible way to avoid stiffness using the ordinary differential
equation solver in Matlab suite. Next, we will discuss some existing mathematical methods to
eliminate stiffness in the singularly perturbed system.
Stiffness

Stiffness is an important concept in the numerical solution of ordinary differential equations
which depends on the differential equation, the initial condition, and the numerical method.
Basically, it affects efficiency, accuracy and graphical output of a computed solution. Generally
speaking, whenever there involves a quickly changing dynamics in some components but not the
others, there is stiffness.
Definition: Stiff Systems

Let

be a constant matrix and

. A linear differential system
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is said to be stiff if and only if
1. For all

the real part of each eigenvalue

of

is negative

2. (Stiffness ratio)
Remark

A general nonlinear problem

is said to exhibit stiffness if the eigenvalues of the Jacobian matrix
fashion. This is because near a particular solution

Define

behave in a similar

we may regard

. Then solves the system

To tackle stiffness in differential equations using the Matlab suite, we employed the
standard differential equation solver ode15s. ODE15s can solve both non-stiff and stiff initial
value problems, and differential algebraic equations (DAEs). ODE15s is a variable order method
solver (Shampine and Reichelt, 1997) – it changes the step size when stiff solutions are
encountered. Note that the code ode15s is a quasi-constant step size implementation of the
numerical differentiation formulas in terms of backward differences. The quasi-constant step size
means that the formulas used are those for a constant step size and the step size is held constant
during an integration step. The syntax of this solver for an initial value problem is,

Here
integration is

is the name of a function that defines the differential equation. The interval of
and the initial conditions are

number of equations by measuring the length of the vector

. The code obtains the

. The vector

is optional
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and it is built by means of the function
commonly used options are relative (

that accepts name-value pairs. The most
) and absolute (

) tolerances associated with the

error control. The default value of relative and absolute error tolerances are

and

respectively. Throughout our simulations, the default values of relative and absolute error
tolerances are used.
Next, we will discuss some mathematical methods to solve stiff systems. Suppose the
assumptions of Hoppensteadt theorem are satisfied, particularly assumption (3), that is, the
algebraic system

has a unique root

with the Jacobian matrix remains strictly

stable (see Chapter 2), then the reduced problem should be computationally simple since
complications of stiffness have been eliminated (Dahlquist 1969; Dahlquist and Soderlind, 1982 ;
Aiken 1985). In our case, the reduced system is as follows,
(2.26)

(2.27)

(2.28)
This reduced system (2.26) – (2.28) can be simulated in Matlab using Runge-Kutta
methods because the solutions of the reduced system are on the same time scale (slow). But we
found that using ode15s reduces the computational time. Thus, we prefer using ode15s in this
system to present simulations in

phase space.

Next, we will discuss another interesting alternative procedure described in (O’Malley,
R.E, 1988). Consider the algebraic system
That is,

from problem (2.23) from Chapter 2.
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Differentiate

with respect to . Then, we get,

That is,

Thus, we have a new set of

differential equations with initial conditions,

Note that these equations eliminated the stiffness because the initial condition has been chosen on
the algebraic surface,

which in turn eliminated the fast dynamics of the problem

(2.22). Moreover, the trajectories of this system lie completely on the surface (slow manifold).
Therefore Runge-Kutta methods work well on this system.
Now, let us rewrite our singularly perturbed system,
algebraic system

Differentiate with respect to ,

This yields,

Thus,

–

. First, consider the
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(4.3)

(4.4)

(4.5)
Note that we could use this system, (4.2) – (4.5) instead of
chosen on the algebraic surface,

–

for initial condition

. This one requirement actually avoids

the fast dynamics of the singularly perturbed system and also forces the trajectories to stay on the
manifold for all

. But as we remarked in the introduction of the numerical simulations that

we use the original system, (2.2) – (2.17) wherever it is possible, so let us choose the initial
condition of TSH from the algebraic surface and use the original system instead of (4.2) – (4.5).
Also from Hoppensteadt theorem, we know that the trajectories of the original system stay near or
on the algebraic surface,

for all

. That is,
(2.2)

(2.10)

(2.15)

(2.17)
We use this model to present numerical simulations in
space.

and

state
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4.3.1

Numerical Simulations of the 4d Model, (2.2) – (2.17)

All numerical simulations are done using parameters from the Table A2 in Appendix A– we will
just alter the parameter

. For the parameter values from Table A2, we obtained

. We will first look at the case when

and investigate the behavior of anti-

thyroid antibody concentrations (Ab) by choosing the initial state exactly at the euthyroid state
except for anti-thyroid antibodies, that is
euthyroid state,

. Note: in

but we chose

in order to use the 4d model. We present

simulations both through time series plots and phase-space diagrams in 3d space. For phasespace diagrams, we mainly use Hoppensteadt’s theorem that the trajectories of the model stay
near the slow manifold (surface)
surface. We use

,

for all time

if we take initial states near or on the

) and

phase space diagrams to

illustrate the results.
We arbitrarily pick the value of

and fix it in the 4d system and then

simulate the model for approximately 2 years. In all our Figures below, the red dot represents the
euthyroid steady state, the green dot represents diseased steady state, the black dot represents the
initial state of the system, and the yellow surface represents slow manifold for

. Figure 4.1

illustrates the 4d system time series plot in which we can see that anti-thyroid antibody
concentration decreases from the initial state (

) and approaches zero in

approximately 350 days while other variables remain at the steady state. Figures 4.2, 4.3 and 4.4
illustrate the 4d system in

) and

phase space. As we

see in Figure 4.2, 4.3 and 4.4, the 4d system moves from the initial state to the euthyroid state for
and the parameter values from Table A2. Note that in Figure 4.3 and 4.4, the dynamics
of 4d system is shown near the slow manifold. In addition, Figure 4.3 and 4.4 shows, the red and
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black dots on the slow manifold, but not the green dot for

and the parameter values from

Table A2.
Next, we arbitrarily pick the value of

and fix it in the 4d system and

then simulate the model for approximately 2 years. This will help us to demonstrate the euthyroid
steady state is no longer attracting the trajectories, but the diseased steady state will emerge into
the rectangular box for that particular

and attract all trajectories with any initial conditions in

the box or positive orthant. Figures 4.5, 4.6, 4.7 and 4.8 illustrate the 4d system moves from the
initial state to the diseased steady state. Figure 4.5 and 4.6 shows the red and green dots on the
slow manifold for
state

. Note in Figures 4.5 and 4.6, the initial state and euthyroid
, is taken to be the same but not in Figures 4.7 and 4.8. Again, as we noted

before, we used parameter values from Table A2 to generate all figures 4.5, 4.6, 4.7 and 4.8. To
generate Figure 4.8, we used the reduced (3d) model, (2.26) – (2.28) instead of the 4d system,
(2.2) – (2.17).

Figure 4.1: Note the thyroid functional size ( is in milliliters. The 4d system, (2.2) – (2.17) with
the initial condition
for the parameter values from Table A2, predicts that Ab
concentration asymptotically approaches zero in approximately 350 days while other variables
remain at steady state. This means that the anti-thyroid antibodies did not affect the function of
the HPT axis.
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Figure 4.2: For
and the parameter values from Table A2, the 4d system, (2.2)
– (2.17) moves from the initial state
to euthyroid steady
state
. Note the thyroid functional size ( is in milliliters.

Figure 4.3: If the initial state
is taken on the slow
manifold, not at euthyroid state, then the 4d system, (2.2) – (2.17) for the parameter values from
Table A2, predicts that the trajectory converges to euthyroid state. This suggests the euthyroid
state is asymptotically stable. Since
, the diseased steady state is not on the surface. Note
the thyroid functional size ( is in milliliters.
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Figure 4.4: We started the 4d system, (2.2) – (2.17) from
=
and the numerical solutions of the system approaches euthyroid state. Since
diseased steady state is located in the negative octant, so we did not plot the green dot
(representing diseased state).

, the

We will now investigate the dynamics of the 4d system, (2.2) – (2.17) by arbitrarily
choosing

.

Figure 4.5: For the initial state
, the 4d system (2.2) – (2.17) for the parameter
values from Table A2 predicts that Ab concentration asymptotically approaches 6800 in
approximately 2 years while other variables start at euthyroid state. Note the thyroid functional
size ( is in milliliters.
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Figure 4.6: For the initial state
and
, the 4d system (2.2) –
(2.17) for the parameter values from Table A2 predicts that euthyroid state becomes unstable, and
the trajectory approaches the diseased state.

Figure 4.7: If the initial state
) is taken on the level
curve, not at euthyroid state, then the 4d system, (2.2) – (2.17) for the parameter values from
Table A2, predicts that the trajectories approaches the diseased state (subclinical hypothyroidism)
while euthyroid state becomes unstable and shows saddle-type behavior. Note the thyroid
functional size ( is in milliliters.

96

4.3.2

Numerical Simulation of the Reduced (3d) Model

Stability of Diseased Steady State

We now present the numerical simulations to support that the diseased steady state is stable when
it is in the positive orthant. For this simulation, we use the reduced system, (2.26) – (2.28) with
parameter values from Table A2 and visualize the trajectories in

phase space.

Figure 4.8: This figure shows the stability of diseased steady state, the initial state was chosen at
. The reduced system, (2.26) – (2.28) approaches the diseased state
via euthyroid state. Note the saddle-like behavior near the euthyroid state. Here,
. Note the thyroid functional size ( is in milliliters.

4.4

Bifurcation Analysis

General Introduction

Bifurcation analysis is in general used for analyzing the qualitative behavior of steady states,
periodic orbits or some other invariant objects, such as a homoclinic or hetroclinic orbit, as
parameters are varied in the system. The usual definition of bifurcation is that a qualitative
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change occurs in the topological nature of the solution, when a parameter passes through a critical
value. That is, the phase portraits or vector field of the dynamical system before and after the
bifurcation are not topologically equivalent. There are two important classes of bifurcations in
literature, namely local and global. Local bifurcations focus on changes that take place near a
steady state or periodic orbit. This is what we will describe here. In our 4d system, we analyze
the qualitative behavior of the steady states as

changes in the system – local bifurcation. There

are several types of local bifurcations that exist in the literature (Strogatz, 1994, Perko, 1991).
Qualitative behavior of the system is typically visualized via a bifurcation diagram. A bifurcation
diagram is a plot which gives a steady state solution as a function of a control parameter. This
plot consists of branches that are either solid or dotted lines representing the locations of stable or
unstable steady states of the system. Importantly, this diagram shows the long-term system
behavior as a control parameter is varied. Next, we will discuss the transcritical bifurcation since
our 4d system undergoes this bifurcation.

Definition: Transcritical Bifurcation

A transcritical bifurcation is a local bifurcation in which two steady states of a model involves in
exchange of stabilities between them.

Example

Consider the 1d system
For

, the steady state

steady state
is unstable and

. This 1d system has two steady states
is stable and

which is structurally unstable. For
is stable (see Figure 4.9).

is unstable. For

and

.

, there is only one

, there are two steady states, but
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Figure 4.9: A bifurcation diagram shows a transcritical bifurcation for a range of values . The
local bifurcation takes place at
.

4.4.1

Bifurcation Analysis of the 4d Model – Varying the Parameter

Why

is a control parameter?

The parameter

in the model is chosen to be a control parameter since the stability analysis of

the 4d system and the biology of the autoimmune thyroiditis suggested this control parameter.
From the biological point of view, the parameter

is involved in the production rate of anti-

thyroid antibodies and it is one of the suitable candidates to choose for bifurcation analysis. Also,
the biology of the autoimmune thyroiditis suggests that parameters

are potential

candidates for bifurcation analysis.
Bifurcation Diagrams

We will now present the bifurcation diagrams of our 4d system which will help us to see the long
- term system behavior as

varied. Basically, the bifurcation diagrams depict the complete

picture of all possible states of the system for large range of values for

. For our 4d system, the

bifurcation diagrams are drawn by plotting the euthyroid steady state and the diseased steady state
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for range of values for

. We observed that when we solve for the steady states in the

introduction of Chapter 4, the euthyroid state is independent of
dependent of
as

and the diseased steady state

. Furthermore, we observed that the stability nature of the steady states changes

varied.
Figures 4.10, 4.11, 4.12 and 4.13 shows how the steady states change as the parameter

is varied. Stable and unstable steady states are drawn as solid and dotted lines respectively. In
particular, Figure 4.10 shows how the anti-thyroid antibodies steady state changes as
the model from 0 to 7. Figure 4.11 shows how free T4 steady state changes as
model from 0 to 7. Figure 4.12 shows how TSH steady state changes as

varies in

varies in the

varies in the model

from 0 to 7. Figure 4.13 shows how the functional size of the thyroid gland steady state changes
as

varies in the model from 0 to 7. All these figures illustrates that the euthyroid state is stable

for the range of values of

from 0 up to

. More precisely, when

, the

euthyroid state is stable. That is, the real parts of the eigenvalues of euthyroid state are negative
between 0 and up to
bigger than

. When

, the euthyroid state is unstable. That is, when

is

, the real parts of the eigenvalues of euthyroid state are negative except in the

direction of anti-thyroid antibodies for the parameter values in Table A2. Note

is the

bifurcation point where the system undergoes an exchange of stability. In other words, the
trajectories of the 4d system before and after
value,

are different. A further important clinical

, will be defined in this discussion. All pictures are drawn with parameter values from

Table A2, except for

is varied.
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Figure 4.10: This bifurcation diagram illustrates how the anti-thyroid antibodies steady state
concentrations
changes as
varies in the model from 0 to 7. Note that the bifurcation
occurs at
.

Figure 4.11: This bifurcation diagram shows how free T4
steady state concentrations
changes as varies from 0 to 7. Observe that the bifurcation occurs at
and when
, we see a patient would have clinical hypothyroidism (see the baseline value of free T4,
shown as a solid magenta line).
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Figure 4.12: This bifurcation diagram shows how
steady state concentrations changes as
varies from 0 to 7. Also, observe that the bifurcation occurs at
and when
,
resulting in clinical hypothyroidism. Thus, the model suggests that at
, TSH upper reference
limit is 2.3 mU/L (approximately). The diseased steady state is still inside the box.

Figure 4.13: This bifurcation diagram shows how the functional size of thyroid gland
as
varies from 0 to 7. Also, observe that the bifurcation occurs at
.

changes
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The bifurcation diagrams depicted the qualitative behavior of our 4d model as

varied

in the system. We found that bifurcation occurred at the numerical value of
for the parameter values from Table A2. In addition, we found that when

increases above the

value 5.2 results in transition to clinical hypothyroidism. Thus, we called this critical value
and it would be where hypothyroidism takes place. In summary, for

, the euthyroid state

is stable and therefore patients with autoimmune thyroiditis do not develop the consequences of
autoimmune thyroiditis (such as subclinical and clinical hypothyroidism). For

,

bifurcation occurs, meaning, the disease steady state and euthyroid state merge each other, so the
patients with autoimmune thyroiditis likely to develop the consequences of the disease in the
future as

changes further. Finally, for

, the euthyroid state becomes unstable and

patients with kinetic parameter in Table A2 with

have autoimmune thyroiditis and

eventually develop hypothyroidism. More precisely, we found that when
results in subclinical hypothyroidism and

is between

and

results in clinical hypothyroidism. Also,

we observed that the bifurcation diagrams predicted the proper upper limit for TSH (2.3) mU/L,
which indicates the validation of the 4d system for Table A2 values.

4.5

Summary

This chapter mainly focused on the stability and bifurcation analysis of 4d system. We derived
conditions for the euthyroid steady state to be stable and unstable in 4d space in the presence of
anti-thyroid chronic immune response. We found that
system undergoes a transcritical bifurcation as

is a bifurcation parameter. The 4d

changes in the system which results in diseased

steady state to emerge in a rectangular box. We have proved that this disease steady state is
locally asymptotically stable. Next, in order to find out the nature of the diseased steady state,
whether subclinical or clinical hypothyroidism, we preformed bifurcation analysis in the 4d
system. This analysis showed that if

, the patients with autoimmune thyroiditis do not
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develop any consequences of the disease and if
thyroiditis develop subclinical hypothyroidism. If

the patients with autoimmune
, the patients with autoimmune

thyroiditis and eventually develop clinical hypothyroidism. This is our main result for this
chapter. In addition, through bifurcation analysis, we found that the upper TSH reference limit
is

mU/L by using the parameter values from Table A2. Note that for numerical simulations

and bifurcation analysis, we used the parameter values from Table A2. This means to say that
each patient’s
different.

and

is different because patient’s euthyroid steady state (set point) is
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CHAPTER 5 – CLINICAL STAGING AND DISEASE PROGRESSION
The goal of this project is to provide a patient-specific description of the natural history of
autoimmune thyroiditis through a mathematical model. What does this mean? It means to
determine the natural course of subclinical or clinical hypothyroidism through a model for each
patient. By using a staging criterion for autoimmune disease patients, we can describe this natural
clinical course. We will first start this chapter with the summary of results of analyzing the
operation of the HPT axis from the previous chapters.


In Chapter 1, we have observed that the hypothalamus-pituitary function is intact and the
thyroid-pituitary function is interrupted in diseased patients. We have used the dataset to
show the motivation of this mathematical modeling project and, in addition, established a
patient-specific clinical staging criterion for diseased patients. The staging criterion has



three cases, namely euthyroidism

euthyroidism, euthyroidism

hypothyroidism and euthyroidism

subclinical

subclinical

clinical hypothyroidism.

In Chapter 2, we have constructed a higher dimensional non-linear model for patients
with autoimmune thyroiditis. The model takes the form of a singularly perturbed initial
value problem. This is the main tool for the analysis of a model, which is elaborated in
this chapter.



In Chapter 3, we looked at the special case of the model, that is, the absence of antithyroid chronic immune response in a singularly perturbed initial value problem– it
mimics the normal axis operation.



In Chapter 4, we have presented the stability analysis of a singularly perturbed initial
value problem. We found that
to the critical value

is a bifurcation parameter. As this parameter changes up

, the individuals with autoimmune thyroiditis do not develop the

consequences of autoimmune thyroiditis, but above the critical value,

, the individuals
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with autoimmune thyroiditis develop subclinical hypothyroidism. Furthermore, we found
another critical value
We will now use

, where patients eventually develop clinical hypothyroidism.

values to relate clinical staging defined in Chapter 1 and along with

that, the numerical simulations are presented to support our staging both via time series plots and
phase space. In time series plots, we will show

values since the hypothalamus-pituitary

function are normal and therefore,

values are more reliable in autoimmune thyroiditis

patients. But, in phase-space both

and free T4

for other clinical variables

The main reason for presenting only

T4

and

will be presented unless there is a need
and free

in phase-space is because these two hormones are measured regularly in the clinical

setting and for treating patients. Thus, after presenting numerical simulations the dataset will be
used subsequently for validating the model prediction.
Case 1
Suppose

, then patients with autoimmune thyroiditis do not develop any clinical

consequences (subclinical or clinical hypothyroidism) and thus a staging will be,
Euthyroidism

Euthyroidism

Case 2
Suppose

then patients with autoimmune thyroiditis develop the subclinical

hypothyroidism. Thus, a staging will be,
Euthyroidism

Subclinical Hypothyroidism

Case 3
Suppose

then patients with autoimmune thyroiditis develop subclinical hypothyroidism

and eventually become clinical hypothyroidism. Thus, a staging will be,
Euthyroidism

Subclinical

Clinical Hypothyroidism
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5.1

Numerical Simulations for Clinical Charts

For numerical simulations, we use a full model with Ode15s solver in Matlab 7.1.1.0 suite.
Case 1: Let us pick arbitrarily ten different

values, less than

and the initial state of the

system is at the euthyroid state except for anti-thyroid antibodies, that is,
.

Figure 5.1: This figure shows Case 1: euthyroidism euthyroidism chart. Note: The solid red
lines illustrate the normal reference range for TSH. The dotted red line chosen for this project as
an upper TSH reference limit. The green solid line indicates that the 4d system, (2.2) – (2.17)
approaches the euthyroid (steady) state for ten different
values less than . The initial state of
the 4d system is
. The parameter values are all from
Table A2 in Appendix A.

Case 2: Let us arbitrarily pick six different
(2.3412) and up to

values

between

and the initial state of the system is at the euthyroid state except for

anti-thyroid antibodies, that is,
from Table A2 to generate the euthyroidism

. We use parameter values
subclinical hypothyroidism chart (see Figure 5.2).
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Figure 5.2: This figure shows euthyroidism subclinical hypothyroidism chart. Note that all
solutions go to subclinical diseased steady state. We simulated the 4d system, (2.2) – (2.17)
with the initial state
and the parameter values from Table A2 with six different
values between
=2.3412 and up to
.

Figure 5.3: 2d view of euthyroidism subclinical hypothyroidism chart. We simulated the 4d
system with the initial state
and the parameter values from Table A2 but
different values, between
=2.3412 and up to
. The curve in this picture is
parameterized by six different values, that is,
. For every
, we have a diseased steady state (subclinical), that is shown in the picture with a green
dot. The euthyroid state is shown in the picture with a red dot.
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Figure 5.4: log

versus freeT4

view of the previous Figure 5.3.

Case3: Let us pick arbitrarily eleven different
17.3, 18.7) values greater than

(5.5, 6.8, 8.14, 9.4, 10.7, 12.1, 13.4, 14.7, 16,

, and the initial state of the system is at the euthyroid

state except for anti-thyroid antibodies, that is,
parameter values from Table A2 to generate the euthyroidism

. We use
subclinical

clinical

hypothyroidism chart (see Figure 5.4).

Figure 5.5: This figure shows the euthyroidism → subclinical → clinical hypothyroidism chart.
To generate this picture, we picked eleven different
values greater than
and then
simulated the 4d system with initial condition
. The parameter values are all
from Table A2.
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Figure 5.6: 2d view of euthyroidism → subclinical → clinical hypothyroidism chart. We
simulated the 4d system with the initial state
and the parameter values from
Table A2 but different
values. The curve in this picture is parameterized by eleven different
values greater than
. For every
, we have a diseased steady state (clinical
hypothyroidism), that is shown in the picture with a green dot. The euthyroid state is shown in the
picture with a red dot. Note an individual progress to clinical hypothyroidism via subclinical
hypothyroidism.

Figure 5.7: log

versus freeT4

view of the previous Figure 5.6.

We will now combine euthyroidism → subclinical hypothyroidism and euthyroidism →
subclinical → clinical hypothyroidism charts and present it as one complete chart.
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Figure 5.8: Clinical staging chart. This chart can be used to determine the natural course of
subclinical or clinical hypothyroidism or euthyroidism by moving the graph up and down
according to the patient’s set point (see Validation of Model with Data Section). Note we
simulated all these curves with different
values in the 4d system using an imaginary
individual’s table parameter values from Appendix A.

Figure 5.9: Combing Figures 5.7 and 5.4 yields the above parameterized curve. This
parameterized curve belongs to an imaginary individual that we picked for this project (see
Appendix A). Since the model (2.2) – (2.17) is patient-specific, each patient has their own curve
depending on their parameter values and the normal value of the HPT axis. The euthyroid state is
shown in the picture with a red dot and diseased steady states are shown with green dots.
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5.2

Discussion of using Patient’s Dataset

We will first discuss how one could determine the euthyroid steady state from patient’s dataset
and next, we will depict how many data points of a patient are required to describe the natural
clinical course of subclinical, clinical hypothyroidism or euthyroidism. Euthyroid steady state
means the set point (normal value) of the HPT axis in the clinical setting. The clinical definition
of the set point is a value of TSH and free T4, within the normal reference range of TSH
and free T4

. Normally, the set point varies between

individuals due to inter and intra variations in the adult population. Suppose if a patient has
several values for TSH and free T4 (of course at different time points) within the reference range,
then our best guess for the euthyroid steady state (set point) is the first data point.
Needless to say, with one data point (say just euthyroid state or set point) of TSH and free
T4, it will be very hard to describe the patient’s clinical course of subclinical, clinical
hypothyroidism or euthyroidism. With two data points of TSH and free T4 at different time
points, one could describe the clinical course using the chart but may not be the better description.
With three or more data points of TSH and free T4 at different time points, one could provide a
better description of patient’s clinical course of subclinical, clinical hypothyroidism or
euthyroidism using the chart. Therefore, we need at least three or more data points in order to use
the chart effectively and make some conclusion about the eventual value (diseased steady state)
of TSH.
In section 5.1, we generated clinical charts using an imaginary individual’s table values
from Appendix A. Recall that our imaginary individual’s euthyroid steady state (set point) is
. Although the euthyroid steady state varies between individuals, the
dynamics of the clinical variables (TSH and free T4) do not change (see Figure 5.11 and 5.12) so
instead of calculating the parameter values for every patient and simulate their own dynamics.
We will just move the clinical chart up and down according to the euthyroid steady state (first
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data point) of the patient (see Figure 5.11) in order to describe the patient’s natural history of
autoimmune thyroiditis.

5.3

Validation of Model with Dataset

Let us consider a patient (#99) from group1 (always untreated patients dataset) for model
validation. We will use euthyroidism

euthyroidism chart for this patient. Patient’s initial

(euthyroid) state is taken to be the first data point of TSH. That is,

.

Figure 5.10: This figure illustrates patient (#99) natural history of euthyroidism in euthyroidism
euthyroidism chart. It seems patient’s
value remains at the euthyroid steady state for 40
months. This patient’s euthyroid state for
value is
mU/L

Let us now consider a patient (#103) from group1 (always untreated patients) and a patient (#114)
from group3 (untreated initially and then received treatment after developed hypothyroidism, see
Chapter1) for model validation. For patient (#103), we will use euthyroidism

subclinical

hypothyroidism chart. For patient (#114), we will use the complete clinical staging chart from
Figure 5.8. In practice, one could move the clinical staging chart up and down according to the
initial (euthyroid) state of the patient, but for numerical simulation one cannot. So, we will choose
the initial state of both patient (#103 and #114) and compute all the parameters as outlined in
Appendix A and simulate the 4d system. The initial state for patient (#103 and #114) is taken to
be the first data point of TSH, free T4, anti-thyroid antibodies and the functional size of the
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thyroid gland. The functional size is chosen in the manner of Appendix A. So, the initial state
for patient (#103) is

. Similarly the initial state

for patient (#114) is

. The model parameter

values are listed in the following Table 5.1 to generate the charts (see Figures 5.11, 5.12). Also
Figure 5.13 and 5.14 illustrate the 2d curve of the patient (#103 and #114) respectively. From
Figures 5.11, and 5.13, we could see that the patient (#103) developed subclinical
hypothyroidism. From Figures 5.12 and 5.14, we could see that the patient (#114) eventually
developed clinical hypothyroidism via subclinical hypothyroidism.
Table 5.1: Parameter Estimated Values, and Units

Name

Patient (#103)
Estimated Value
5000

Patient (#114)
Estimated Value
5000

16.6355

16.6355

100

100

0.099021

0.099021

1

1

1

1

0.035

0.035

0.039

0.074034

0.0083

0.0147

58.516

96.505

Note: the parameters

are the same numbers as in Appendix A. To generate the

chart, Figure 5.11, we used six different
(2.485) and

. Note

Unit

and

values

between

values changed a bit for patient (#103). Similarly to

114
generate the complete clinical chart in Figure 5.12, we used fourteen different

values,

. For patient (#114),
and

.

Figure 5.11: This figure illustrates patient (#103) natural course of subclinical hypothyroidism in
euthyroidism subclinical hypothyroidism chart. It seems this patient’s TSH value continuously
increases as time increases. By looking at 3 data points in this chart, we could predict that TSH
cannot go beyond
mU/L at least for 40 months. Thus, this patient may have chance to become
subclinical hypothyroidism throughout his life time unless there is some triggering event that
changes the nature of the immune response and thus .

Figure 5.12: This figure shows the natural history of patient (#114). This patient reaches clinical
hypothyroidism via subclinical hypothyroidism. Note this patient’s TSH value increases
continuously but did not exceed mU/L in 40 months.
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Figure 5.13: To generate this 2d picture, log
(mU/L) versus free T4
(pg/mL), we
simulated the 4d system with patient (#103) parameter values from Table 5.1. Here
was
and the initial (euthyroid) state was
. Note:
the diseased steady state is located within the normal free T4 reference range. So, the model
predicts that the patient (#103) may remain in subclinical hypothyroidism unless the immune
response of this patient changes in the future.

Figure 5.14: To generate this 2d picture, log
(mU/L) versus free T4
)(pg/mL), we
simulated the 4d system with patient (#114) parameter values from Table 5.1. Here
was
and the initial (euthyroid) state was
. Note:
the diseased steady state is not located within the normal free T4 reference range. So, the model
predicts that the patient (#114) will definitely become a clinical hypothyroidism patient in the
future.
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5.4

Results and Summary

In this chapter, we related a patient-specific clinical staging with a model. We mainly presented
charts, namely, euthyroidism

subclinical hypothyroidism chart and euthyroidism

subclinical

clinical hypothyroidism chart and a combined chart involving only TSH and time (months),
because in autoimmune thyroiditis, the hypothalamus-pituitary function is intact. These charts
can be used in thyroid clinics to predict the natural clinical course of subclinical or clinical
hypothyroidism in autoimmune patients. For that, we need at least three data points of TSH with
respect to three different time points. This means, in simple language, that a doctor, using the
TSH test, may be able to distinguish between those who will not develop thyroid problems and
those who may become thyroid patients. Furthermore, the doctors will be able to treat sooner
those destined for autoimmune thyroiditis related diseases. In addition, we presented the
parameterized curve involving free T4 and TSH phase space.
From the mathematical viewpoint, the goal of this project is to identify a curve based on
TSH that an autoimmune patient follows as time changes. This curve predicts whether a patient
progress to subclinical or clinical hypothyroidism diseased state. If this curve is known, then
patient diseased dynamics is known to physicians and thereby plans for treatment (free T4
replacement) can be developed based on TSH test results. For a physician’s convenience, we
simulated a lot of curves for different

values in the clinical staging chart (see Figure 5.8). This

may help physicians to visualize patient’s TSH curve over time. This charting method for test
results of TSH could be used to predict the ultimate level of thyroid destruction, and thyroid
hormone production.
Future Work


Examine the relationship between the high levels of TSH in autoimmune patients and
follicular thyroid cancer initiation.



Relating genetics of this disease to model results.
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Appendix A

Parameter used for Simulations.
To illustrate the general results in this dissertation, we would like parameter values consistent
with our data and the literature. We remark in chapter 2 that the system (2.2) – (2.17) has eleven
parameters, some of them are available from the literature, some are calculated, and some are
determined experimentally using equilibrium value of an adult individual to match the expected
behavior of a normal thyroid. We will now reveal how the example parameter values are
estimated. Suppose a normal adult has an equilibrium value of
, then the unknown parameter values of this adult can be computed around the
equilibrium value.
Consider the equation (2.2),

The first term accounts for the secretion rate of
excretion rate of

and the second term accounts for the

. It has three parameters namely

The parameter
than

.

is available from the medical literature (Faglia, 1987). It is greater
. For this study, we will choose

for all adults in the population. The meaning of
stimulating hormone

and fix this number

is the largest possible secretion rate of thyroid

from the pituitary in the absence of free thyroxine

.

Biologically, this condition means clinical hypothyroidism (myxoedema).
The parameter

is calculated using

(2.2). The biological meaning of

chemical half-life (about 1 hour) in equation

is the rate at which

Neglecting the secretion rate in (2.2), gives

disappears from the blood.
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The solution of this rate equation is,

where

is the initial value of

in the blood. The half-life is the time that concentration

of a quantity takes to fall to 50% of the initial value in the blood. Using

half-life, we obtain,

That is,

The parameter value of
value of

can be computed experimentally by using the equilibrium

. Thus, set

and solve for

which yields

values, that is,

. Utilizing the equilibrium value and the parameter
,

. We determined the value of

,

and

, that is,

.

Consider the equation (2.10),

The first term accounts for the secretion rate of free
of free

. It has three parameters namely
The parameter

The half-life of free
The parameter
set

is calculated similar to
is about 7 days. Thus,

and the second one for the excretion rate
.
by using the chemical half-life of free

is found to be

.

.

is calculated using both the equilibrium and limiting argument. First,
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This gives

Since

quickly approaches the equilibrium value in the blood, so we will take a limit of the

above equation, that is,

From this limiting equation, we can solve for

We can further use
The parameter

Note that: if

and

to obtain

is computed experimentally similar to

, then

than
and

,

.

. By setting

. To avoid this situation, I picked
. And then use

. This gives a value of

,

a little bit greater
,

.

Consider the equation (2.15),

The first term accounts for the growth rate of the active thyroid gland and the second account for
the destruction rate of the functional thyroid gland. The equation has again three parameters
namely

and . Now, setting
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and using

,

be

,

is calculated to

. Note that the euthyroid state (steady state) in Chapter 3 or Chapter 4 is

independent of the parameters
of

. The value of

and

and

. So we could pick any value for

and

. The value

does not change the stability of the euthyroid state. Thus, we will pick
.

Consider the equation (2.17),

The first term accounts for the production rate of anti-thyroid antibodies due to the destruction of
active thyroid gland and second term accounts for aging rate of anti-thyroid antibodies. This
equation has two parameters namely
The parameter

and

.

is an important parameter in the model. We used the value of this

parameter to describe the natural clinical course of subclinical or clinical hypothyroidism in adult
population. We studied this parameter in detail in Chapter 4. Thus, the reader should refer to
Chapter 4.
The parameter

is calculated using the half-life (about 20 days) of anti-thyroid

antibodies in equation (2.17). The biological meaning of

is the rate at which anti-thyroid

antibodies disappears from the blood. This parameter can be calculated just like
Thus,

and

.
Table A1 list the imaginary individual’s variable values, range, units and sources.

Similarly Table A2 lists the parameter values for that particular imaginary individual.
Table A1: Variable Normal Values, Ranges, Units and Sources

Name

Normal
Value
1
13
0.015

Normal Range
–

Source
Literature(Baloch etal. 2003)
Literature(Baloch etal. 2003)
Literature(Carle etal. 2009)

Unit

.
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Dataset

Table A2: Parameter Estimated Values, Ranges, Units, and Sources

Name

Estimated
Value

Normal
Range

Source
Literature (Faglia, 1987)
Literature (Greenspan and
Gardner, 2001)
Simulation
Literature(Greenspan and
Gardner, 2001)
Simulation
Simulation
Literature
Calculation/Simulation
Simulation
Calculation

Unit
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Appendix B

Solving Cubic Equation
In this Appendix, we will outline a method to solve a cubic equation (see Selby, 1969). Suppose a
cubic equation is given in the form
substituting

into the cubic equation and reduce to the form,

where,

and

For solution let

and

and

then the values of

will be given by,

, then we will solve for

by
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,

,

Now, we can of course convert from the
If

solutions to the

solutions using the equation (c1).

are real, then:

If

, there will be one real root and two conjugate imaginary roots

If

, there will be three real roots of which at least two are equal

If

, there will be three real and unequal roots

Descartes’ Rule of Signs (Murray, 2002)

Consider the polynomial in the general form,

where the coefficients

,

are all real and

. Let M be the number of sign

changes in the sequence of coefficients

, ignoring any which are zero. Descartes’

Rule of Signs says that there are at most M roots of

, which are real and positive, and further,

that there are M, M-2 or M-4,… real positive roots. By setting

and again applying the

rule, information is obtained about the possible real negative roots. Together these often give
invaluable information on the sign of all roots, which from a stability point of view is usually all
we need.
Example: While solving for the euthyroid steady state, we encountered the cubic polynomial of
the form,
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Note: M=1, because the equation

has only one sign change in the sequence of coefficients
. Therefore, by Descartes’ rule there is exactly one

real positive root. If we now set

, the equation

becomes,

That is,

There are two sign changes in the sequence of coefficients and so there are either two or zero real
negative roots.
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Appendix C

Data Sets

File Name

File Description

NewData.xslx

119 Hashimoto’s thyroiditis patients raw dataset

NOPT.mat

This file contains patient’s identification number (Id), time (Time),
thyroid stimulating hormone (TSH), free thyroxine (FT4), and antithyroid antibodies (TPOAb and TGAb). There are 119 Hashimoto’s
thyroiditis patients in this dataset. It is created from NewData.xslx file.

group1scaled.mat

Always untreated patient’s dataset is created from NOPT.mat file.
This dataset contains Id, Time, TSH, FT4, TPOAb and TGAb. Note:
group1 patient’s TSH and FT4 values are all scaled to normal
reference range of TSH:
and FT4:
.

group2scaled.mat

group3scaled.mat

Treated patients from time zero is created from NOPT.mat file. This
dataset contains Id, Time, TSH, FT4, TPOAb and TGAb. Note:
group2 patient’s TSH and FT4 values are all scaled to normal
reference range of TSH:
and FT4:
.

Untreated patients initially and then received treatment with
Levothyroxine after developed hypothyroidism. This dataset is
created from NOPT.mat file. It contains Id, Time, TSH, FT4, TPOAb
and TGAb. Note: group3 patient’s TSH and FT4 values are all scaled
to normal reference range of TSH:
and FT4:
.

group3scaleduntreated.mat

Group3 patients’ dataset before treatment. It is created from
group3scaled.mat file

patient99.mat

Patient #99 data is extracted from group1scaled.mat file (always
untreated patients dataset).
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patient103.mat

Patient #103 data is extracted from group1scaled.mat file (always
untreated patients dataset).

patient114.mat

Patient #103 data is extracted from group3scaleduntreated.mat file.

Matlab Files

File Name

File Description

scatterplots.m

This Matlab file contains codes for all scatter plots in Chapter 1.

normal_operation.m

This Matlab file contains codes for simulating the reduced 2d model in
Chapter 3.

norm_operation.m

This Matlab file contains codes for simulating 3d model when Ab set to zero
in Chapter 3.

Disr_feed.m

Using this Matlab file, one could generate all figures in Chapter 4. Note that
and
value changes for different arguments.

bifurcation.m

Using this file, one could generate all bifurcation diagrams in Chapter 4.

euthyroid.m

Using this file, one could generate euthyroidism
Chapter 5.

euthyroidism chart in

subclinicalhypo.m

Using this file, one could generate euthyroidism subclinical
hypothyroidism chart and the parameterized curve (by ) in Chapter 5.

clinicalhypo.m

Using this file, one could generate euthyroidism subclinical clinical
hypothyroidism chart and the parameterized curve (by ) in Chapter 5.

completechart.m

Using this file, one could generate the complete euthyroidism subclinical
clinical hypothyroidism chart and the parameterized curve (by ) in
Chapter 5.
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patient103.m

Using this file, one could generate patient #103 clinical chart and the curve in
TSH- FT4 phase plane.

patient114.m

Using this file, one could generate patient #114 clinical chart and the curve in
TSH- FT4 phase plane.

All files are available in the following Url:
http://www.mscs.mu.edu/~stevem/bala_files.html

